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of this review is to focus on the different existing animal 
models of neurodegenerative disorders, describe behavioral 
tests and preclinical imaging techniques used for diagnose 
and describe the vascular pathological features associated 
to these diseases.
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test · Preclinical imaging · Mice · Neurovascular 
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Abbreviations
ALS  Amyotrophic lateral sclerosis
AD  Alzheimer’s disease
PD  Parkinson’s disease
HD  Huntington’s disease
Iba1  Ionized calcium binding adapter molecule 
1
PET  Positron emission tomography
CT  Computed tomography
MRI  Magnetic resonance imaging
BBB  Blood–brain barrier
SPECT  Single photon emission computed 
tomography
CBF  Cerebral blood flow
fMRI  Functional magnetic resonance imaging
CBV  Cerebral blood volume
BOLD fMRI  Blood oxygenation level dependent fMRI
MRA  Magnetic resonance angiography
TOF  Time-of-flight MRA
CE  Contrast enhanced
OI  Optical imaging
WR  Wobbler
pmn  Progressive motor neuronopathy
SOD  SuperOxide dismutase
VEGF  Vascular endothelial growth factor
Abstract Neurodegenerative diseases represent great 
challenges for basic science and clinical medicine because 
of their prevalence, pathologies, lack of mechanism-based 
treatments, and impacts on individuals. Translational 
research might contribute to the study of neurodegenerative 
diseases. The mouse has become a key model for studying 
disease mechanisms that might recapitulate in part some 
aspects of the corresponding human diseases. Neurode-
generative disorders are very complicated and multifacto-
rial. This has to be taken in account when testing drugs. 
Most of the drugs screening in mice are very difficult to 
be interpretated and often useless. Mouse models could 
be condiderated a ‘pathway models’, rather than as models 
for the whole complicated construct that makes a human 
disease. Non-invasive in vivo imaging in mice has gained 
increasing interest in preclinical research in the last years 
thanks to the availability of high-resolution single-photon 
emission computed tomography (SPECT), positron emission 
tomography (PET), high field Magnetic resonance, Optical 
Imaging scanners and of highly specific contrast agents. 
Behavioral test are useful tool to characterize different ani-
mal models of neurodegenerative pathology. Furthermore, 
many authors have observed vascular pathological features 
associated to the different neurodegenerative disorders. Aim 
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VEGFR2  VEGF receptor 2
SN  Substantia Nigra
FMU  Flow metabolism uncoupling
ADC  Apparent diffusion coefficient
TSPO  18 kDa translocator protein
Aβ  Beta amyloid
APP  Amyloid precursor protein
MWM  Morris water maze
CAA  Celebral amyloid angiopathy
NIRF  Near infrared fluorescence
6-OHDA  6-hydroxydopamine
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine
PQ  Paraquat
DAT  Dopamine transporter
SNpc  SN pars compacta
VMAT2  Vesicular monoamine transporter 2
MRE  Magnetic resonance elastography
GABA  Gamma amino butirric acid
18F-DOPA  6-18fluoro-L-3,4-dihydroxyphenylalanine
MSNs  Medium spiny neurons
QA  Quinolinic acid
3-NP  3-Nitropropionic acid
YAC  Yeast artificial chromosomes
NO  Nitric oxide
O2−  Superoxide
mGluR  Metabotropic glutamate receptor
CEST  Chemical exchange saturation transfer
PDE10A  Phosphodiesterase 10A
Introduction
Neurodegenerative diseases are among the main causes of 
mental and physical disabilities in humans (for review, see 
Kreiner 2015). Although there is no substitute for studying 
real human biology, animal models provide opportunities 
for experimentation that are often not possible in human 
patients and represent a critical platform upon which 
translational efforts for treating human neurodegenera-
tive diseases are built (Arora et al. 2011). Indeed, trans-
genic animals carrying human mutations provide a unique 
opportunity to understand the pathogenetic mechanisms 
underlying human disease (Luo et al. 2016; Southwell 
et al. 2017). The quality or utility of a model often depends 
on its validity, and the assessment of cognitive abilities 
is an important aspect of the validation and experimental 
use of models for neurocognitive disorders, as well as to 
evaluate cerebral microvascular aberrations that are rec-
ognized as playing a role in neurodegenerative disorders 
(Dorr et al. 2012; Miyazaki et al. 2012; Sarkar et al. 2014). 
The most used animal models of neurological disorders, 
with the related characteristic lesions, are summarized in 
Table 1. Exploring the relationship between neuromuscu-
lar degeneration and behavioral/motor tests is a useful and 
important step in identifying the clinical characteristics 
of mice models (Grant et al. 2014). The most commonly 
used behavioral tests, divided according to the different 
neurodegenerative mice models of disease, are summa-
rized in Table 2.
Preclinical imaging allows the evaluation of neurodegen-
erative aspects and of vascular alterations at different time 
points, the study of neuropathological evolution even before 
the onset of the symptoms, and the evaluation of pre- and 
post-symptomatic therapies. Preclinical imaging approaches 
related to the different animal models of neurological dis-
eases are summarized in Table 1.
Clinical brain computed tomography (CT) and mag-
netic resonance imaging (MRI) scans routinely demon-
strate impaired regions of the blood–brain barrier (BBB) 
as focal areas of “contrast enhancement.” Brain tumors and 
abscesses, sub-acute strokes, and active multiple sclerosis 
lesions are recognized by local contrast enhancement. In 
these instances, the signal-to-noise ratio for the contrast 
agent in the region of localized BBB impairment is very 
high (Bowman and Quinn 2008).
Functional imaging modalities, such as single photon 
emission computerized tomography (SPECT), positron 
emission tomography (PET) and MRI, are useful in assess-
ing the early phases of disease (Fig. 1). Both PET and 
SPECT are sensitive methods for measuring in vivo neu-
rochemistry; PET cameras has spatial resolution of about 
1–2 mm, while SPECT can get a submillimeter spatial reso-
lution using dedicated multipinhole geometry (for review, 
see Khalil et al. 2011).
The most suitable method to detect abnormalities in 
mouse models of cerebrovascular disorders is MRI because 
the reduction of the T2 relaxation time has been shown to be 
associated with reduced cerebral blood flow (CBF) (Help-
ern et al. 2004). Preclinical MRI is used to highlight the 
presence of plaques in the brain or areas of atrophy typi-
cal of neurodegenerative disorders (Wadghiri et al. 2012; 
Li et al. 2016; Santin et al. 2016). Functional MRI (fMRI) 
allows the non-invasive analysis of brain function in humans 
and animals, evaluating the cerebral blood volume (CBV), 
CBF and blood oxygenation level (blood oxygenation level 
dependent – BOLD – fMRI) and is also used to assess 
hemodynamic changes in response to therapies. Moreover, 
magnetic resonance angiography (MRA) comprises differ-
ent techniques applied to evaluating vascular architecture, 
e.g., time-of-flight (TOF) MRA is used to study the major 
cerebral arteries (Fig. 2). Signal voids in TOF-MRA may 
indicate an absence of flow, low flow velocity, or turbulent 
flow. Contrast-enhanced (CE) MRA is used to analyze brain 
vessel architecture with fewer flow and motion artifacts than 
TOF-MRA (Mellin et al. 1994; Lin et al. 1997).
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Table 2  Behavioral tests of most common alterated function in animal models of neurodegenerative diseases
Behavioral test Neuro-sensory-motor-function Models References
Grid walking Voluntary motor control
Coordination and accurate paw 
placement
Wobbler
MPTP
(Starkey et al. 2005; Meredith et al. 
2008; Taylor et al. 2010; Moser 
et al. 2013)
Grip Muscle strength
Motor performance
pmn
TgCRND8
(Kennel et al. 2000; Bellucci et al. 
2006)
Rotarod
Stride length
Motor coordination
Motor function
Wasted
SOD1
Thy1-APP751
TgCRND8
APP 23
arcAß
MPTP
Parkin deficient
DJ-1
Rotenone
3-Nitropropionic acid
YAC 128
N171-82Q
CAG150
EAE
TMEV- induced
Toxin-induced demyelination
(Fernagut et al. 2002; Van Dam et al. 
2003; Chen et al. 2005; New-
bery et al. 2005; Van Raamsdonk 
et al. 2005; Bellucci et al. 2006; 
Liebetanz and Merkler 2006; Wang 
and Qin 2006; Knobloch et al. 
2007; Ramaswamy et al. 2007; 
Heng et al. 2008; Lynch et al. 
2008; Gorton et al. 2010; Knip-
penberg et al. 2010; Taylor et al. 
2010; Cheng et al. 2011; Havas 
et al. 2012; Franciosi et al. 2012; 
Miyazaki et al. 2012; Acharjee et al. 
2013; Lee et al. 2013; Takemiya 
and Takeuchi 2013; Evans et al. 
2014; Rial et al. 2014; Abakumova 
et al. 2015; Liu et al. 2015; Oliván 
et al. 2015; Stover et al. 2015; Gilli 
et al. 2016; Paz Soldán et al. 2015)
Hanging wire Muscular strength of the limbs SOD1
CAG150
(Heng et al. 2007; Günther et al. 
2012; Oliván et al. 2015)
Morris water maze Spatial learning and memory hAPP
Thy1-APP751
Tg-SWDI
APP/London
PSAPP
3xTg-AD
APP 23
arcAß
APP/PS1
Paraquat
Quinolinic acid
R6/2
EAE
(D’Hooge and De Deyn 2001; Van 
Dam et al. 2003; Kumar-Singh et al. 
2005; Giménez-Llort et al. 2007; 
Knobloch et al. 2007; Ramaswamy 
et al. 2007; Busche et al. 2008; 
Bryan et al. 2009; Philipson et al. 
2010; Havas et al. 2012; Litteljohn 
et al. 2011; Gu et al. 2012; Hall 
and Roberson 2012; Acharjee et al. 
2013; Iascone et al. 2013; Passos 
et al. 2013; Thomason et al. 2013; 
Li et al. 2014)
Y maze
T maze
Novel object recognition test
Reference and working memory PSAPP
PDAPP
APP Dutch
5XFAD
TgCRND8
Tg-SWDI
arcAß
Parkin deficient
Quinolinic acid
R6/2
YAC 128
(Van Raamsdonk et al. 2005; Oakley 
et al. 2006; Knobloch et al. 2007; 
Ramaswamy et al. 2007; Bryan 
et al. 2009, Hall and Roberson 
2012; Passos et al. 2013; Romberg 
et al. 2013; Webster et al. 2013; 
Beauquis et al. 2014; Burgess et al. 
2014; Girard et al. 2014; Rial et al. 
2014; Knight et al. 2015)
Olfactory tubing maze Learning and memory 5XFAD (Roman et al. 2002; Girard et al. 
2014)
Barnes maze Spatial learning and memory TgAPParc
5XFAD
(Rönnbäck et al. 2011; Xu et al. 
2014)
Righting reflex Defects of neuromuscular junction
Synapse maturation and vestibulo-
spinal input
Wobbler (Bose et al. 1998; Moser et al. 2013)
Hole board Exploratory activity
Neuromuscular functions
TgCRND8
Thy1-APP751
(Bellucci et al. 2006; Havas et al. 
2012)
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Table 2  (continued)
Behavioral test Neuro-sensory-motor-function Models References
Radial arm water maze Reference and working memory Quinolinic acid
N171-82Q
(Ramaswamy et al. 2007; Webster 
et al. 2013)
Pole Coordination MPTP
Parkin deficient
α-synuclein
Rotenone
Paraquat
3-Nitropropionic acid
(Fernagut et al. 2002, 2007; Fleming 
et al. 2004; Luchtman et al. 2009; 
Taylor et al. 2009, 2010; Rekha and 
Selvakumar 2014; Rial et al. 2014; 
Liu et al. 2015)
Open field
Bar test
Locomotor and spontaneous activ-
ity
R6/2
YAC 128
CAG140
PDAPP
TgAPParc
3xTg-AD
Tg2576
APP 23
arcAß
MPTP
DJ-1
α-synuclein
Rotenone
Paraquat
3-Nitropropionic acid
Thy1-APP751
(Fernagut et al. 2002; Van Dam et al. 
2003; Fleming et al. 2004; Chen 
et al. 2005; Van Raamsdonk et al. 
2005; Giménez-Llort et al. 2007; 
Knobloch et al. 2007; Ramaswamy 
et al. 2007; Deacon et al. 2009; 
Luchtman et al. 2009; Taylor et al. 
2009, 2010; Havas et al. 2012; Lit-
teljohn et al. 2011; Rönnbäck et al. 
2011; Hickey et al. 2012; Kishi-
moto et al. 2013; Lee et al. 2013; 
Beauquis et al. 2014; Kudo et al. 
2014; Rekha and Selvakumar 2014; 
Liu et al. 2015)
Footprint analysis Gait abnormalities SOD1
CAG150
EAE
(Buddeberg et al. 2004; Heng et al. 
2008; Knippenberg et al. 2010; 
Oliván et al. 2015)
Climbing Coordination CAG150 (Hickey et al. 2012; Rattray et al. 
2012)
Wheel running Motor deficits CAG150
Toxin-induced demyelination
(Liebetanz and Merkler 2006, Hickey 
et al. 2012; Switonski et al. 2012)
Tail suspension Depressive behavior CAG150
Parkin deficient
(Heng et al. 2007; Iascone et al. 2013; 
Rial et al. 2014)
Balance beam Motor coordination and balance CAG150 (Heng et al. 2008; Luong et al. 2011)
Elevated plus maze
Light–dark exploration
Marble burying
Anxiety 3xTg-AD
APP Dutch
MPTP
Parkin deficient
Toxin-induced demyelination
(Giménez-Llort et al. 2007; Gorton 
et al. 2010; Taylor et al. 2010; Li 
et al. 2014; Rial et al. 2014; Aba-
kumova et al. 2015; Knight et al. 
2015)
Forced swimming Depressive behavior Parkin deficient (Rial et al. 2014)
Grasping strength Motor function Parkin deficient (Rial et al. 2014)
Adhesive tape removal
von Frey filament
Motor response to sensory stimuli DJ-1
α-synuclein
TMEV- induced
(Fleming et al. 2004; Chen et al. 
2005; Lynch et al. 2008; Taylor 
et al. 2010)
Challenging beam traversal Motor performance and coordina-
tion
Paraquat
α-synuclein
(Brooks et al. 1999; Fleming et al. 
2004; Fernagut et al. 2007; Taylor 
et al. 2010)
Inverted grid Motor coordination α-synuclein (Fleming et al. 2004; Taylor et al. 
2010)
Bin cotton use Motor performance and coordina-
tion
α-synuclein (Fleming et al. 2004)
Solid gastric emptying
Stool collection
Gastrointestial disfunction Rotenone (Taylor et al. 2010; Liu et al. 2015)
Water & food finding Social memory Tg2576 (Deacon et al. 2009; Kishimoto et al. 
2013)
Buried pellet
Olfactory discrimination
Olfactory function MPTP
α-synuclein
Parkin deficient
(Taylor et al. 2010; Rial et al. 2014)
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Another approach to studying neurodegenerative dis-
orders is in vivo optical imaging (OI) using transgenic 
mouse models, which express a reporter gene, e.g., green 
fluorescent protein, under a promoter that has the abil-
ity to be activated, which should represent a disease bio-
marker. This imaging approach has the advantages that 
it avoids radiation and radiolabeled tracers/agents, does 
not require complex surgical techniques and is cheaper 
than other imaging techniques (for review, see Patterson 
et al. 2014).
This review summarizes the most common mouse 
models of neurodegenerative diseases, describing the neu-
rovascular component involved in these pathologies and 
presenting the diagnosis and grading methods adopted to 
evaluate these animal models accurately, such as behav-
ioral tests and in vivo imaging techniques.
Mouse models of amyotrophic lateral sclerosis
ALS is a fatal neurodegenerative disease characterized 
by the selective and progressive death of both upper and 
lower motor neurons, leading to progressive paralysis (for 
review, see Tovar-y-Romo et al. 2009). In mouse models of 
ALS, specific motor tasks are indispensable for the detec-
tion of disease onset and early progression (Knippenberg 
et al. 2010). Although body weight has been indicated as a 
useful additional parameter, in particular to monitor disease 
progression during later stages (Knippenberg et al. 2010), 
Table 2  (continued)
Behavioral test Neuro-sensory-motor-function Models References
Cylinder
Stepping
Forelimb akinesia 6-OHDA (Andringa et al. 2005; Boix et al. 
2015)
Corridor
Rotation test
Sensory-motor function 6-OHDA (Boix et al. 2015)
Touch-screen automated tests 
battery
Visual, memory, attention, cogni-
tive
TgCRND8 (Romberg et al. 2013)
Fig. 1  [18F]FDG and  [18F]FECT probabilistic atlases. a Series of 
axial sections (ventral to dorsal, slice interval 1.2  mm, radiological 
orientated) through the mouse brain MRM atlas (top row) and co-reg-
istered  [18F]FDG (middle row) and  [18F]FECT (bottom row) small-
animal PET template. b One representative coronal (radiological 
orientation) and sagittal slice through caudate-putamen. c Horizontal 
section through variance map at level z = 22.8 (relative to bregma). 
The mouse brain MRM atlas shows the pre-defined VOI map over-
layed. Color bars indicate relative intensities for  [18F]FDG; binding 
potential for  [18F]FECT. (Casteels et al. 2013)
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weight loss is a symptom that cannot be attributed exclu-
sively to a neurodegenerative disease.
The oldest known model that shows similarities with 
human ALS is the wobbler (WR) mouse, in which neurons 
of the spinal cord, brainstem and motor cortex are affected 
(Moser et al. 2013). The severity of motor neuron defects 
is assessed by evaluating the mouse performance in the 
grid walking and righting reflex tests (Bose et al. 1998), 
indeed, WR mice develop severe problems in grabbing and 
climbing the grid due to their progressive muscle weak-
ness, and rapidly lose the righting reflex (Bose et al. 1998; 
Ott et al. 2015).
Fig. 2  Magnetic resonance angiography with 3D rendering acqui-
sition of the orbital region. Upper row: (a) axial and (b) coronal 
computed tomography slice. Lower row: 3D rendering of magnetic 
resonance angiography acquisition of the left orbital region ((c) 
antero-lateral view). 3D rendering of silicon-enhanced computed 
tomography angiography ((d) lateral view). (a), (b), The large retro-
orbital venous plexus (white arrow) is clearly visible as well its drain-
age into the posterior facial vein ((c), (d) white arrow). (d) The super-
ficial temporal vein is also shown in (Mancini et al. 2015)
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Another ALS model is the mouse progressive motor neu-
ronopathy (pmn) mutant, developing from a spontaneous 
autosomal recessive mutation that maps to mouse chromo-
some 13 (Schmalbruch et al. 1991). Clinical signs in pmn 
homozygotes are identifiable 2–3 weeks after birth, includ-
ing profound paralysis of the hind limbs and atrophy of the 
pelvic girdle, as displayed by grip test, and almost all distal 
axons disappear 4–5 weeks after birth (Kennel et al. 2000).
Mice bearing the autosomal recessive gene “wasted” 
(wst/wst), mimic the sporadic ALS form. The wst/wst 
mouse develops low or absent secretory immune responses, 
abnormal DNA repair mechanisms, and uncoordinated 
body movements (Woloschak et al. 1987). The wst/wst mice 
is characterized by prominent vascular degeneration of neu-
rons within the anterior horns of the spinal cord and the 
motor nuclei of the brain stem, and neuropathologic stud-
ies showed deficit with rotarod test (Newbery et al. 2005).
Both familial ALS and 5% of apparently sporadic ALS 
seem to be associated with the gene encoding the enzyme 
 Cu2+/Zn2+ superoxide dismutase (SOD1). Indeed, the 
most similar mouse model is  SOD1G93A, which develops 
a progressive paralysis starting from the hind limbs via 
denervation of the neuromuscular junctions. In contrast to 
the variable pattern of weakness recorded in humans, in 
the SOD1 mutant mice, weakness typically starts in the 
hind limbs between 3 and 12 months of age, depending on 
both the mutation  (SOD1G85R,  SOD1G37R, and  SOD1G93A) 
and the level to which it is expressed. Hindlimb weakness 
coincides with increased astrogliosis, the activation of 
microglia, and the loss of spinal cord motor neurons. The 
pathology in these mice closely mimics many aspects of 
the human disease (Evans et al. 2014). In humans, ALS 
predominantly affects males, probably due to differences 
between men and women in the nervous system or in its 
response mechanisms to environmental stimuli. Gender 
differences in the motor impairment in  SOD1G93A mice 
have recently been demonstrated through behavioral tests; 
in particular, female mice endured the disease progression 
better (Choi et al. 2008). However, the gender effect on sur-
vival is an open debate (Kirkinezos et al. 2003; Choi et al. 
2008; Knippenberg et al. 2010). The clinical phenotype, 
detection and monitoring of motor symptoms in  SOD1G93A 
mice have been perfectly characterized by the conventional 
behavioral tests: rotarod, footprint analysis and hanging-
wire, which represent the most accurate tests to monitor the 
disease progression in this transgenic model (Knippenberg 
et al. 2010; Oliván et al. 2015). Furthermore, to classify 
disease stages, a scoring system was developed by Ver-
celli et al. (2008). The  SOD1G93A G1H transgenic mouse is 
a widely used animal model of familial human ALS (Zang 
et al. 2004). In this model, the primary pathology is linked 
to the degeneration of lower motor neurons (LMNs) in the 
lumbar spinal cord and brainstem (Lowry et al. 2001).
Evidence of vascular changes in ALS
Vascular endothelial growth factor (VEGF) and the expres-
sion of the VEGF receptor 2 (VEGFR2) are essential in 
angiogenesis during embryonic development as well as 
in pathological conditions such as stroke, acute ischemia, 
ischemic neuropathy and many cancer histotypes (Oost-
huyse et al. 2001; Zhao and Adjei 2015). The potential 
role of VEGF in ALS has been illustrated in several stud-
ies utilizing different variants of SOD1 mutation models, 
e.g., cell culture models and knock-in and knock-out mouse 
models (for review, see Keifer Jr et al. 2014). The majority 
of these studies have focused on the VEGF-A and VEGF-
B isoforms, considering the larger literature establishing 
their neurotrophic role (Oosthuyse et al. 2001; Poesen et al. 
2008). The first study to evaluate the therapeutic poten-
tial of VEGF for the treatment of ALS was conducted by 
Azzouz et al. (2004), who showed that a single injection of 
a VEGF-expressing lentiviral vector into various muscles 
slowed the progression of ALS in  SOD1G93A mice, even 
when treatment was initiated at the onset of paralysis. The 
VEGF treatment increased the life expectancy of ALS mice 
by 30% without causing toxic side effects, and the intraperi-
toneal injection of VEGF has been shown to delay disease 
progression and increase survival in  SOD1G93A transgenic 
mice (Azzouz et al. 2004). Mice homozygous for the dele-
tion of VEGF suffer severe muscle weakness in adulthood 
due to degeneration of the lower motor neurons innervating 
skeletal muscle fibers, reminiscent of the clinical symptoms 
and neuropathological signs of ALS. In these mice, the neu-
ropathy may be due to chronic ischemia resulting from neu-
rovascular perfusion deficits but may also be exacerbated by 
insufficient VEGF-dependent neuroprotection, and thus the 
abnormal expression of VEGF may constitute a previously 
unknown risk factor for motor neuron degeneration (Oost-
huyse et al. 2001). Within the  SOD1G93A mouse spinal cord, 
a reduction in VEGF and VEGFR2 expression, with loss of 
large motor neurons, has been observed (Lunn et al. 2009). 
Similar reductions are evident in human patients with ALS 
(Brockington et al. 2006). Another confirmation of the role 
of VEGF in the pathogenesis of ALS is given by exposure to 
low doses of environmental lead (Pb) (Barbeito et al. 2016). 
Although Pb is a well-known risk factor for ALS, sub-toxic 
Pb concentrations up-regulate VEGF expression (Barbeito 
et al. 2016). Chronic exposure to sub-toxic Pb concentra-
tion did not affect disease onset but significantly increased 
life expectancy (by 12 days) in  SOD1G93A mice. This result 
suggests that Pb might be involved in a novel pathway that 
can reduce neuroinflammation and slow neurodegeneration 
in ALS.
Damage to the vasculature is one of the earliest pathologi-
cal events in the toxic cascade initiated by both dismutase-
active and -inactive SOD1 mutants, and such changes at the 
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vascular level probably make an important contribution to 
the degeneration of the large motor neurons in models of 
familial ALS (Zhong et al. 2008). Targeted deletion of the 
hypoxia-response element in the VEGF gene resulted in 
mice with a normal baseline expression of VEGF but a pro-
nounced deficit in the ability to induce VEGF up-regulation 
in response to hypoxia. Motor neuron deficits first appear 
in mice between 5 and 7 months of age and then gradually 
progress. All the classic features of ALS are observed: accu-
mulation of neurofilaments in spinal and brainstem motor 
neurons, degeneration of motor axons, and the characteristic 
denervation-induced muscle atrophy (Lunn et al. 2009).
Among the vascular-related pathophysiological mecha-
nisms underlying ALS, flow metabolism uncoupling (FMU), 
which is characterized by an initial blood flow reduction and 
local glucose utilization increase in the spinal cord of ALS 
mice, has recently been considered to precede the sequential 
changes of the disease (Miyazaki et al. 2012).
FMU has been shown to be strongly correlated to decreas-
ing capillary diameter and density, as well as to neurovas-
cular unit disruption within the anatomical regions affected 
by ALS. Although the reason for the presence of FMU in 
SOD1 mice is unclear, it might be profoundly involved in the 
overall disease process, as suggested by the aforementioned 
correlations, and should be explored as a potential target for 
therapeutic intervention (Miyazaki et al. 2012).
Preclinical imaging in ALS
A recent clinical study revealed neuronal loss and reduced 
axonal density in the primary motor cortex in ALS patients 
through MRI analysis (Meadowcroft et al. 2014). MRI is a 
valid tool even in characterizing animal models of ALS, as it 
has been demonstrated to allow evaluation of the pre-sympto-
matic period (Evans et al. 2014). Neuronal degeneration of the 
brainstem motor nuclei was visualized in T2-weighted MRI 
acquisitions: hyperintense areas visualized regions of cerebral 
neurodegeneration, which were found primarily in the brain-
stem (Zang et al. 2004). Stronger hyperintense regions were 
discovered primarily in three cranial nerve nuclei: the nucleus 
ambiguus, the facial nerve nucleus and the motor trigeminal 
nucleus. Such hyperintense areas in the brainstem indicate 
areas of neurodegeneration. On the other hand, hypointensi-
ties, indicative of diffuse atrophy, were detected in the brain 
and cerebellum (Zang et al. 2004). Moreover, the T2 MRI 
sequence showed a reduction in the number of neurons in the 
substantia nigra (SN) in SOD1. The MRI results allowed the 
prediction of deficits in vocalization, mastication and swal-
lowing in the  SOD1G93A G1H transgenic mice, in which the 
clinical evaluation of such symptoms is not easy. These symp-
toms occur similarly in bulbar onset patients, who show voice 
and/or swallowing difficulties in the first phase of the disease; 
hence, preclinical MRI has proven useful in detecting thie 
analogy between human and mice (Zang et al. 2004).
Although the signal strength was correlated with disease 
progression, T2-weighted MRI does not provide an absolute 
quantification, and it is useless for studying damage to the 
spinal cord. A useful tool to complement the T2 data is the 
apparent diffusion coefficient (ADC), which provides infor-
mation regarding brain tissue integrity based on measuring 
water mobility (Niessen et al. 2006). In contrast to the T2 
measurements, the ADC values are generally influenced by 
the animals’ age, leading to increases in nucleus V, nucleus 
VII, and nucleus XII, in the motor cortex, and in the thalamus 
of  SOD1G93A compared to wild-type mice (Niessen et al. 
2006). The combination of ADC and T2 mapping enable the 
longitudinal non-invasive evaluation of disease progression 
in the  SOD1G93A. The MRI signal alterations appear in dif-
ferent critical brain regions, e.g., the brainstem and spinal 
cord, early in the course of the disease, when the animals are 
still clinically unremarkable (Niessen et al. 2006).
To date, preclinical MRI allowed only the identification 
of structural/anatomical damages, and no vascular altera-
tions have been documented yet. Ex vivo transmission elec-
tron microscopy, immunihistochemical and immunofluores-
cence studies of murine models of ALS have highlighted 
the presence of various alterations in the neurovascular 
unit in the spinal chord (Zhong et al. 2008; Miyazaki et al. 
2011). Anyway, the T1 CE-MRI of  SOD1G93A mice did not 
show any increase in vascular permeability, as confirmed by 
immunohistochemistry, in any of the cerebral regions stud-
ied (Evans et al. 2014).
In addition to its diagnostic usefulness, MRI was used in 
tracking stem cells injected into mice with ALS. The admin-
istration of stem cells is a promising novel approach for the 
treatment of neurodegenerative diseases, seeking to replace 
lost or dysfunctional neurons. The intraspinal injection of 
adult stem cells from human umbilical cord blood into the 
spinal cord prolongs survival, delays the deterioration of 
motor function and prevents motor neuron loss and astro-
cytosis in SOD1 transgenic mice (Knippenberg et al. 2012). 
Thus, clinical trials to confirm the same effects in human 
beings would be desirable.
In vivo two-photon microscope imaging of spinal cap-
illary vessels showed decreases in both the diameter and 
density of capillary vessels, which resulted in a progres-
sive decrease in flow volume in SOD1 mice (Miyazaki et al. 
2012). Nonetheless, the impact of abnormal vascularity as 
well as neuroinflammatory processes on axonal degeneration 
in the peripheral nervous system remains elusive.
Time-lapse 2-photon laser-scanning microscopy is a use-
ful imaging approach, which allows analysis of the role of 
macrophage-related neuroinflammation and reactive micro-
glia. The increase in microglia presence, the ameboid trans-
formation, the loss of tissue surveillance and the decrease in 
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the injury-directed movement process, all of which promi-
nently occur during the human clinical course, emphasize 
the contribution of microglia to disease progression in SOD1 
animals in the late phase of the disease (Dibaj et al. 2011).
In vivo OI in bi-genic mice  (SOD1G93A:GFAP-luciferase) 
showed several successive stages of repeated increases in the 
expression of GFAP. The pre-symptomatic stage is charac-
terized by an increase in GFAP-luciferase, with prominent 
signaling emitted by the lumbar spinal cord projections and 
peripheral neurons. The clinical onset is characterized by 
distinct behavioral deficits and hind-limb paralysis. The fluo-
rescence peak signal at 113 days corresponded precisely to 
the onset of hind-limb paralysis. These results suggest that 
populations of non-neuronal cells, perhaps glial cells, can 
affect the viability of motor neurons (Keller et al. 2009). 
Moreover, an increased signal contribution from the corti-
cospinal tract and upper motor neurons was shown by OI, 
with the approach of the end stages of the disease. Micro-
tubule associated protein 1 light chain 3 is a marker of 
autophagy, which, fused to green fluorescent protein, might 
be used to study in vivo autophagy in  SOD1G93A mice (Wei 
2014).
The PET/CT approach is useful in evaluating the patho-
logical and inflammatory processes in ALS mice, including 
the modulation of glutamatergic function (Brownell et al. 
2015). Imaging of the inflammatory response was per-
formed using translocator protein 18 kDa (TSPO) ligand 
 [11C]-PBR28, an imaging ligand for the translocator protein, 
which is a biomarker for inflammation and activated micro-
glia: the most significant enhancement was detected in the 
brain and spinal cord, during progression of the disease in 
 SOD1G93A (Brownell et al. 2015). Recently, an increased 
 [18F]-DPA-714 uptake in cerebellum and brainstem was 
demonstrated in vivo, proving the feasibility and sensitiv-
ity of  [18F]-DPA-714 for the study of 18 kDa transloca-
tor protein (TSPO) expression and of microglial activation 
in the brain and spinal cord of transgenic  SOD1G93A with 
PET/CT, probabily linked to the ionized calcium binding 
adapter molecule 1 (Iba1) microglial overexpression (Gar-
giulo et al. 2016). The brainstem is known to be a site of 
degeneration and gliosis in ALS patients, consistent with 
the increased TSPO expression in the brainstem nuclei, 
as shown by immunostaining (Gargiulo et al. 2016). The 
TSPO, also known as peripheral benzodiazepine receptor, 
is a protein of the outer mitochondrial membrane associ-
ated to nucleoside transport and steroids and neuroster-
oids synthesis (for review, see Jacobs et al. 2012). In the 
normal brain, the TSPO is globally low expressed, and its 
up-regulation is a biomarker of activated microglia (Diorio 
et al. 1991, for review, see; Jacobs et al. 2012). Its diag-
nostic importance in neurological diseases is linked to the 
possibility to bind it specifically with several radioligands, 
both for PET and SPECT imaging, i.e.  [11C]-DAA1106, 
 [18F]-FE-DAA1106,  [11C]-DPA-713,  [18F]-DPA-714, 
 [ 18F]-PBR28,   [ 18F]-PBR111,   [ 11C]-SSR18075, 
 [11C]-CLINME,  [123I]-CLINDE, and  [11C]-vinpocetine 
(Diorio et al. 1991).
Mouse models of Alzheimer’s disease
The AD is a neurodegenerative disease accounting for 
50–75% of dementia cases. As of 2015, approximately 
44 million people worldwide were estimated to have AD or 
related dementia (for review, see Van Cauwenberghe et al. 
2015). The disease is clinically characterized by progres-
sive deterioration of the memory and cognitive functions, 
leading to loss of autonomy and ultimately requiring full-
time medical care (Cheng et al. 2015). To date, there are no 
known viable treatments for this condition, but an appropri-
ate lifestyle can help to prevent this disease. To understand 
the biological mechanisms underlying this disease, several 
mouse models have been developed, although no existing 
model exhibits all the features of AD.
The first and the most widely used mouse models of AD 
are based on the transgenic expression of human amyloid 
precursor protein (hAPP). In general, these strains develop 
robust amyloid pathology, show memory deficits, and exhibit 
depressive behavior at the tail suspension test (Iascone et al. 
2013). However, the mice also exhibit deficits in spatial 
memory, as observed in the Morris water maze (MWM) test 
for hippocampus-dependent memory (Iascone et al. 2013). 
They resemble the synaptotoxicity of AD but do not typi-
cally exhibit significant neuron loss, since beta-amyloid (Aβ) 
oligomers are known to act as a potent CNS neurotoxins, via 
specific disruption of neuronal signal transduction, without 
loss of cell bodies, as demonstrated by array tomography (for 
review, see Klein 2002; Lacor et al. 2004; for review, see; 
Mucke and Selkoe 2012). Moreover, the synaptotoxic role of 
Aβ is furtherly supported by the Aβ-immunotherapy favora-
ble effects on memory and neurite architecture in AD mouse 
models (for review, see Spires-Jones and Knafo 2012). The 
promoters driving hAPP expression, the hAPP isoform(s) and 
mutation(s) expressed, and the background strain are among 
the differences between hAPP lines (Hall and Roberson 2012).
The Thy1-APP751 model express high levels of mutant 
hAPP751 under the control of the mThy1 promoter. This 
mouse model is characterized by plaques onset at 3 months 
of age, when dense amyloid deposits appear in the frontal 
cortex, while extensive amyloid deposits in most of the neo-
cortex, hippocampus, thalamus, and cerebellum are devel-
oped by 9 to 11 months of age (Rockenstein et al. 2001). The 
early plaques onset makes this model ideal for the study of 
anti-amyloidogenic drugs.
The Tg-SwDI mouse is obtained by a triple mutation of 
the hAPP gene, i.e. Swedish K670N/M671L, Dutch E693Q, 
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and Iowa D694N mutations (Montgomery et al. 2016), and it 
develops amyloid plaques by 2 to 3 months of age, which are 
extensive by 12 months of age (Gu et al. 2012; Van Vickle 
et al. 2008). The Tg-SwDI mouse develops extensive fibril-
lar Aβ deposits primarily in cerebral micro vessels, whereas 
non-fibrillar plaques are predominantly diffuse in the brain 
parenchyma (Van Vickle et al. 2008). These features make 
the model useful for studying the progression of plaque for-
mation and the predisposing factors (Gu et al. 2012).
The TgCRND8 mice carry the Swedish KM670/671NL and 
Indiana V717F mutations in the Aβ precursor encoding gene. 
The brain areas mainly affected are those rich in cholinergic fib-
ers, i.e. the stratum radiatum of the hippocampus and the corpus 
callosum. The cholinergic damage is closely linked to the spread 
of amyloid plaques, which are detected by 7 months of age, and 
mirrors AD pathology in patients (Bellucci et al. 2006).
The Tg2576 mice express the human 695-amino acid 
isoform of AβPP bearing the double Swedish mutation (Lu 
et al. 2016). By 12 months of age, the Tg2576 mice develop 
progressively β amyloid plaques, gliosis and astrocytosis, 
with decreased glucose utilization and oxidative stress in 
the cerebral cortex (Apelt et al. 2002).
The PDAPP model mirrors the early onset AD form and 
it is characterized by the expression of human V717F muta-
tion in the APP gene under the control of the PDGF pro-
moter (Redwine et al. 2003). These mice show parenchymal 
amyloid plaques spreading by 6 to 9 months of age, and 
this diffusion progresses between 12 and 25 months of age, 
without any neuronal loss (Reilly et al. 2003). Furthermore, 
amyloid plaques have a structure that resembles those of 
AD patients, making this model useful for deeply studying 
amyloid plaques (Reilly et al. 2003).
The APP Dutch model with E693Q mutation under the 
Thy-1 promoter develops CAA, neuroinflammation and 
hemorrages, but it is not suitable to study amylioid deposi-
tions; indeed, Aβ levels are to low for amyloid precipitation 
and deposits formation (Kumar-Singh et al. 2000). The APP 
London model is characterized by hAPP London mutant 
overexpression exclusively in neurons, and mice bearing such 
mutation develop amyloid plaques at 12–15 months of age and 
vascular amyloid between 13 and 24 months of age (Dewachter 
et al. 2000). The amyloid vascular diffusion increases with 
age, and this feature allows studying new therapies to prevent 
vascular amyloid deposits (Van Dorpe et al. 2000).
The APP23 mouse, carrying the hAPP with the Swedish 
double mutation, develops plaques predominantly in the neo-
cortex and the hippocampus, and it displays activated micro-
glia, hypertrophic astrocytes, axonal sprouting and dystrophic 
neurites. Furthermore, by 14 months of age, this model 
develops hippocampal neuronal loss and vascular amyloid 
deposition (Van Dam et al. 2003; Mahler et al. 2015).
The TgAPParc is a mouse model that expresses APP 
with Arctic mutation (E693G). The Aβ-neuropathology 
onset in the subiculum and after spreads to interconnected 
limbic brain regions over 3–15 months. The TgAPParc is 
useful in order to understanding the spread and progres-
sion of Aβ neuropathology mechanism in AD (George 
et al. 2014).
The arcAb mouse develops age-dependent Aβ accumulation 
both in cerebral parenchyma and vessels. Six months old arcAβ 
mice show the first intracellular punctate deposits Aβ deposits in 
the cortex and hippocampus, later between 9 and 15 months of 
age, β amyloid plaques are prominent. The development of Aβ 
deposits in this model is used to evaluate amyloids deposition 
mechanism in AD (Knobloch et al. 2007; Klohs et al. 2013).
Presenilin mutations have also been used to develop mouse 
models of AD. Presenilin mutant mice crossed with hAPP trans-
genic mice exhibit extensive plaque deposition and behavioral 
deficits. A prototype is the PSAPP line, derived from a cross 
between transgenic mice expressing the M146L presenilin muta-
tion and the hAPP transgenic mouse line Tg2576. This line devel-
ops Aβ plaque deposition earlier than Tg2576 and has increased 
Aβ42 levels. The PSAPP mice have deficits in the Y-maze even 
before plaque deposition, a finding that separates cognitive defi-
cits from plaque burden (Holcomb et al. 1998). Today, the com-
bined injection of the presenilin and hAPP transgenes as a single 
transgene is a more commonly used approach than breeding the 
presenilin and the hAPP mutant mice. The combined introduc-
tion of transgenes can be achieved either with two constructs, 
each with its own promoter element, coinjected into the pronu-
cleus, or with transgenes cloned into one vector, separated by 
an internal ribosomal entry site and placed under the control of 
a single promoter (Jankowsky et al. 2004). The 5XFAD mice 
express high levels of Aβ42 and develop amyloid pathology and 
cognitive deficits by 4 months, and they show impaired memory 
in the Y-maze. In addition, the 5XFAD line develops neuron loss, 
unlike most other hAPP and hAPP/PS1 models. Thus, 5XFAD 
mice rapidly recapitulate major features of AD amyloid pathol-
ogy and may be useful models of neurodegeneration and amyloid 
plaque formation (Oakley et al. 2006). On the other hand, an 
age-dependent increase in Aβ deposition has been documented 
in AβPP/PS1 mice, and these animals display cognitive deficits 
at the age of 6 months (Zhang et al. 2012).
The most commonly used behavioral tests to evaluate AD 
deficits are the MWM test, which evaluates spatial memory in 
rodents, and the Y- and T-maze tests, often used to test work-
ing memory. In AD mouse models, the recognition test has 
also been evaluated. The latter test is an easier and potentially 
more sensitive method to evaluate compound effects (Zhang 
et al. 2012). In addition to memory impairment, this disease 
causes additional symptoms, and therefore, other tests, such as 
a touch screen-based automated test battery, have been studied 
to evaluate attention deficits, which have been confirmed in 
both TgCRND8 mice and 3xTgAD mice (Romberg et al. 2013).
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Evidence of vascular changes in AD
Epidemiological and clinico-pathological data suggest over-
laps between AD and cerebrovascular lesions. Such lesions 
may magnify the effect of mild AD and promote the progres-
sion of cognitive decline, or may even precede neuronal dam-
age and dementia. Vascular pathology in AD, as well as in 
the aging brain, includes cerebral amyloid angiopathy (CAA) 
and microvascular changes (for review, see Jellinger 2002). 
CAA is the most common pathological finding, present in up 
to 90% of AD patients (for review, see Jellinger 2002; Vinters 
1987). Both AD and CAA can lead to pronounced cerebro-
vascular dysfunction, characterized by the impaired neuro-
vascular and metabolic regulation of CBF and aberrations in 
vascular morphology and density. Mouse models that better 
represent CAA are Thy1-APP751, Tg-SwDI, and TgCRND8, 
whereas late-onset CAA, i.e., after 9 months of age, is usually 
detected in mice expressing mutated APP restricted to one 
familiar mutation, as in Tg2576, PDAPP, APPDutch, APP/
London, APP23, or TgAPPArc animals.
Tg2576 mice represent an optimal model to mimic cere-
brovascular conditions that commonly occur in AD patients, 
allowing the visualization with MRA of blood flow abnor-
malities in the middle cerebral artery (Kara et al. 2012), 
and amyloid plaques, which might play a role in the cer-
ebrovascular alterations observed in AD (Kara et al. 2012). 
Tg2576 mice develop age-dependent cerebrovascular dys-
function, with the most severe deficits noted in aged mice 
having extensive CAA, and the impairment is directly cor-
related with the extent of CAA (Fig. 3) (Milner et al. 2014). 
The APP model shows varying degrees of CAA, which 
appears in aged animals and can be used to determine the 
inter-relationship between CAA, parenchymal amyloid 
pathology and vascular deterioration associated with aging 
(Li et al. 2014). The TgCRND8 model develops Aβ plaques 
in the parenchyma by 3 months of age, and by 7–10 months 
of age, both the number of vessels with CAA and the extent 
of Aβ deposition along the vessel walls increase significantly 
(Hawkes and McLaurin 2009).
The APP23 model shows alterations in cerebrovascular 
angiogenesis, and by 20 months of age, it shows vascular 
rearrangement and replacement in the posterior cerebral 
arteries. In the latter model, an increase in the number of 
cerebral vessels expressing markers of angiogenesis was 
detected. This mechanism is probably triggered by blood 
vessel damage (Thomason et al. 2013). The arcAβ mice 
develop intracellular Aβ deposits by 3 months of age and 
develop dense cored Aβ plaques starting at 7 months old, 
coinciding with the development of severe CAA (Kno-
bloch et al. 2007). By 24 months of age, fibrinogen accu-
mulation in vessels, indicating neurovascular damage, was 
detected. Furthermore, this mouse model shows a progres-
sive decrease in endothelial glucose transporter 1, mainly in 
vessels with CAA (Thomason et al. 2013). The APP Dutch 
model is characterized by Aβ deposits predominantly located 
in the vasculature, with rare parenchymal plaques. Cerebral 
blood vessels show a thickened basement membrane, due 
to amyloid fibril deposition, and a loss of vascular smooth 
muscle cells (Thomason et al. 2013).
The CAA is often associated with cerebral microhemor-
rhages, which occur as a result of weakened vessel walls 
due to amyloid pathology. For increased understanding of 
cerebral microhemorrhages, there are some mouse models, 
such as Tg2576, that develop cerebral microhemorrhages 
Fig. 3  Angiograms collected at 17.6  T magnet of 18-month-old 
transgenic mice showing various level of severities of morphological 
changes appointed in 3D MIP. The number indicates the appointed 
score to the level of severity of alterations. For example: 1 = a flow 
disturbance (as seen in AComA in image a); 2 = a small signal void 
(as observed at the origin of AComA in image b); 3 = more than two 
small voids in same artery (as observed on the MCA on both sides in 
image b); 4 = an extended void (as observed in the external carotid 
artery on both sides in image a); 5 = a combination of an extended 
void and several small signal voids (as observed in the external 
carotid artery on both sides in image b); 6 = the signal is no longer 
visible (as shown at the pterygo portion of the pterygopalatine artery 
in image a and b). The enlarge view of alterations is shown in (c). 
(d) MCA alteration mean score in control and Tg2576 mice with age. 
Values are mean ± SE (error bars); one-tail student T test; *Pb0.05; 
n = 4 (Kara et al. 2012)
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between 15 and 24 months of age, in addition to CAA. The 
APP23 model also shows cerebral hemorrhages between 14 
and 27 months of age, whereas in arcAβ mice, hemorrhages 
are infrequent (Thomason et al. 2013).
Preclinical imaging in AD
Transgenic mouse models of AD have become essential 
bio-systems for developing and defining optimal imaging 
approaches to visualize AD pathology in vivo, as well as 
for understanding the genotype–phenotype interaction in 
this disease (for review, see Benveniste et al. 2007). Most 
in vivo experiments have focused on the role of amyloid 
plaques, which are insoluble protein aggregates occupying 
the interneuronal spaces in brain tissue (Bigot et al. 2013).
Numerous imaging methodologies have been applied to 
evaluate the effect of plaques on the vascular system. Luo 
et al. showed for the first time, using fMRI, a correlation 
between the presence of Aβ40 and the decrease in CBV 
(Luo et al. 2008). The MRI studies performed in vivo using 
mouse models of AD proved to be a useful tool to visualize 
Aβ plaques using a T2-weighted sequence, and the contrast 
between plaques and normal-appearing adjacent brain tis-
sue, defined as “local magnetic susceptibility,” is presum-
ably related to the iron that resides within most plaques 
(Chamberlain et al. 2009). Bigot et al. reported magnetiza-
tion transfer contrast MRI, a technique derived from MR 
spectroscopy, as a novel approach to detect amyloid plaques 
in vivo (Bigot et al. 2013). Another approach to imaging Aβ 
plaques has been to target the plaques with specific MRI 
contrast agents that cross the BBB (Martins et al. 2013). 
The ideal MRI contrast agent for visualizing and quantify-
ing the pathological burden of Aβ plaque should have four 
properties: (1) high in vivo stability, (2) ability to cross the 
BBB nondestructively following intravenous injection, (3) 
specific binding to plaques with high affinity, and (4) ability 
to produce local changes in tissue contrast that are detect-
able by MRI (Poduslo et al. 2002). The best mouse model 
for studying Aβ plaques is the APP/PS1 mouse, with plaque 
formation beginning at 3 months of age. The systemic injec-
tion of Aβ40 peptide chelated to gadolinium (Gd), after 
intravascular co-injection with mannitol to transiently open 
the BBB, can be used to detect Aβ plaques by µMRI in the 
brains of AD transgenic mice (Wadghiri et al. 2013). The 
T2-weighted and T2-star-weighted µMRI protocols have 
been used because they allow the clear identification of 
hypointense lesions, corresponding to Aβ plaques identi-
fied at histology, with relatively short acquisition times, i.e., 
1 to 2 h. However, this method detected the plaques at an 
advanced stage and thus does not allow diagnosis of the dis-
ease at an early stage. To overcome mannitol pre-injection 
or the administration of any other agent to induce specific 
BBB permeation, ultrasmall superparamagnetic iron oxide 
nanoparticles chelated to polyethylene glycol linked to Aβ42 
contrast agent can be used to image amyloid plaques and are 
therefore more suitable for longitudinal studies in the AD 
model, as well as for its ability to distinguish the plaques 
from the blood vessels (Wadghiri et al. 2013).
Although in vivo microscopic techniques are a valid 
tool for differentiating CAA from neuritic deposits, such 
techniques are invasive and therefore confined to yielding 
mechanistic information in animals (for review, see Klohs 
et al. 2014). Nonetheless, they constitute an important 
complement for macroscopic imaging approaches such as 
PET and MRI, which can also be used in humans. Even 
with high field MRI, it is difficult to analyze deposits less 
than 35 µm, which is critical for the early diagnosis of 
CAA (Jaruszewski et al. 2014). Monocrystalline iron oxide 
nanoparticles have been used to detect CAA, but not for 
its treatment, and such nanoparticles cannot be used as 
PET or SPECT contrast agents. To avoid these problems, 
specific nanovehicles have been designed and labeled with 
the novel amyloid antibody IgG4.1, which can target CAA 
and can serve as both an early diagnostic and therapeutic 
agent. These nanovehicles were chelated with Gd-based 
MRI contrast agents, or SPECT agents, such as 125iodine 
(I). In addition, they could be used for drug delivery and 
anti-inflammatory therapy (Kandimalla et al. 2007). In 
particular, the F(ab′)24.1 fragment of IgG4.1 is grafted 
onto the polymeric core of nanovehicles to aid the tar-
geting to cerebrovascular amyloid (Agyare et al. 2008). 
Although MRI is a useful tool to assess brain atrophy, 
alterations in perfusion, and various brain networks in AD, 
it is not the imaging modality of choice for visualizing 
microglia activation (James et al. 2015).
The  [11C]-PIB compound readily passes the BBB and rap-
idly clears from normal brain tissue, and it is useful for the 
imaging of β-amyloid plaques in transgenic mice, even if its 
specificity is highly dependent on the model and the plaque 
structure (for review, see Waerzeggers et al. 2010; Manook 
et al. 2012; Snellman et al. 2013). Indeed, it binds not only 
to classical and diffuse β-amyloid plaques, but also to CAA 
lesions (Lockhart et al. 2007).
The cerebral glucose metabolism, measured by  [18F]-FDG 
PET, is one of the most sensitive functional biomarkers of 
AD (Poisnel et al. 2012). AD patients display early and 
progressive reductions of glucose metabolism in cortical 
and hippocampal regions (Poisnel et al. 2012). The 3xTG 
mouse model is a useful model, as it mimics the brain glu-
cose uptake abnormalities of AD patients (Nicholson et al. 
2010). In contrast, in APP/PS1, the  [18F]-FDG PET showed 
an age-related increase of uptake in the cortex in the hip-
pocampus and in the striatum (Poisnel et al. 2012). Imaging 
with FDG PET showed hypermetabolism associated with 
elevated taurine concentrations, revealed by proton MRS, in 
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Tg2576 mice. Using fMRI for CBV calculation, the integrity 
of the cerebral vascular compliance in 7-month-old Tg2576 
versus WT was confirmed. The Tg2576 mouse brain hyper-
metabolism seems to be unrelated to changes in vascular 
compliance, but it may be due to a primary central nervous 
system process related to amyloid hyperproduction. Taken 
together, these data suggest that the utility of the Tg2576 
model may be limited to studying production and clearance 
mechanisms, rather than neuronal metabolism (Luo et al. 
2012).
Light-based microscopy methods allow collecting infor-
mation at very high resolution, but they are restricted to 
superficial cerebral areas, i.e. the cortex, during in vivo 
microscopy. These techniques are also limited by the pres-
ence of the skull, hence they need an optical window, such 
as thinned bone areas or craniotomy. On the other hand, 
near-infrared fluorescence (NIRF) allows three-dimensional 
study of deeper brain structures, at the expenses of spatial 
resolution (for review, see Klohs et al. 2014). In Tg2576 
mice, the CAA evolution has been studied through multipho-
ton microscopy, and it has been shown to start by 9 months 
of age and to progress linearly between 9 and 16 months 
(Robbins et al. 2006). Amyloid specific dyes, typically used 
for histopathological evaluation, can be chemically modified 
to obtain imaging probes for amyloid deposition detection 
in vivo (for review, see Klohs et al. 2014). Fluorescent dyes 
transit time was prolonged in TgCRND8 mice compared 
to wildtype littermates, suggesting impaired cerebral perfu-
sion, which can be studied with two-photon microscopy as 
well as with laser Doppler flowmetry (Dorr et al. 2012). 
Spatial frequency domain imaging and diffuse optical imag-
ing allowed quantitative measurement of oxy- and deoxy-
hemoglobin concentrations in 3xTg-AD mice, showing that 
even if normal aging produce a significant decrease of such 
parameters in the brain of control mice, their reduction is 
always superior in AD mice (Lin et al. 2014).
An example of NIRF application was the study of the 
drug efflux transporter ATP-binding cassette sub-family G 
member 2 (AbcG2), a transmembrane protein that seems 
to operate as a controller at the BBB level preventing Aβ 
entering the brain parenchyma from bloodstream. In fact, 
it has been demonstrated that knock-out AbcG2 mice accu-
mulate significantly more Aβ compared to control mice. On 
the other hand, both Tg-SwDI and 3XTg-AD mouse models 
displayed an increased expression of the AbcG2, suggesting 
that Aβ accumulation might be due to an impaired clearance 
as well as to an over deposition (Xiong et al. 2009). Micro-
glial cells and blood vessels staining was obtained in vivo 
by high pressure injection of tomato lectin conjugated with a 
fluorescent dye into the cortex of an APP23 cross transgenic 
model, as well (Busche et al. 2008; Schwendele et al. 2012).
Mouse models of Parkinson’s disease
Parkinson’s disease (PD) is the second most common neuro-
degenerative disorder, affecting approximately 0.3% of the 
entire population, 1% of people over 60 years of age and up 
to 4% of people over 80 years of age (for review, see Mao 
et al. 2015). PD is caused by progressive degeneration of 
the nigrostriatal dopaminergic pathway, leading to dopamine 
deficiency. When the deficit reaches 80%, clinical symptoms 
appear. There are 2 principal mouse models of PD. The first 
requires the use of neurotoxins and replicates most of the 
pathological and/or phenotypic features of PD in mammals; 
the second is genetic and models monogenic forms of famil-
ial PD (for review, see Bogaerts et al. 2008).
The toxic models of PD are developed using the toxins 
6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), rotenone, paraquat (PQ) or 
epoxomicin. The toxin 6-OHDA shares some structural 
similarities with dopamine and norepinephrine, exhibit-
ing a high affinity for several catecholaminergic plasma 
membrane transporters such as the dopamine transporter 
(DAT) and norepinephrine transporter. Its administration 
causes nigrostriatal depletion and gliosis when stereotacti-
cally injected into the SN, median forebrain bundle or stria-
tum (for review, see Waerzeggers et al. 2010). Following 
6-OHDA injections into the nigrostriatal tract, dopaminergic 
neurons start degenerating within 24 h, and striatal dopa-
mine is depleted 2 to 3 days later (Faull and Laverty 1969). 
Although the 6-OHDA model is a valid tool for the develop-
ment of new therapeutic strategies, it does not mimic all the 
clinical and pathological features characteristic of PD, such 
as the formation of Lewy bodies and cytoplasmic inclusions. 
Furthermore, the acute nature of the experimental model dif-
fers from the progressive degeneration of the dopaminergic 
nigral neurons (for review, see Betarbet et al. 2002).
The most common animal model for studying PD is the 
MPTP mouse model. MPTP is a potent and irreversible 
mitochondrial complex I inhibitor whose toxic metabolite 
MPP + is selectively transported by the DAT and whose 
administration results in Parkinsonism (for review, see 
Waerzeggers et al. 2010). The MPTP model is a valid tool 
for studying the mechanism of dopaminergic neuronal death 
and testing neuroprotective agents, but its major limitation, 
which is shared by the toxic models in general, is that the 
SN pars compacta (SNpc) lesion is not accompanied by 
the formation of Lewy body-like cytoplasmic inclusions 
(Muñoz-Manchado et al. 2016). Meredith et al. developed a 
chronic MPTP model with the concomitant administration of 
probenecid, in which a significant reduction in the number of 
neurons in the SNpc, the loss of 50% of dopamine neurons 
and the reduction of striatal dopamine levels by 90 − 95% 
were demonstrated (for review, see Meredith et al. 2008).
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The PQ and rotenone administration in mouse pro-
duce specific feature of human PD, due to oxidative stress 
(Sharma et al. 2006; Fernagut et al. 2007). The PQ model 
shown a reduction in ambulatory movement, and Rotenone 
induce a progressive and chronic degeneration of the nigros-
triatal pathway similar to what is observed in humans due to 
systemic complex I inhibition (Liu et al. 2015).
The genetic PD models are α-synuclein mice, parkin 
knockout mice, DJ-1 knockout mice, Nurr1 and PITX3-
aphakia mice. The α-synuclein transgenic mouse shows 
variable neuropathological and behavioral phenotypes. The 
main feature of this model is the manifestation of the typi-
cal motor dysfunction of PD, although the dopaminergic 
and behavioral defects depend on the level of expression 
of the transgene in both the neuronal and glial populations 
(Fernagut and Chesselet 2004).
The “parkin” mutation causes the most common auto-
somal recessive form of PD (for review, see Blandini and 
Armentero 2012). As several studies have shown that the 
knockout mouse models for the parkin gene showed impair-
ment of the short-term spatial memory and hippocampal 
synaptic plasticity, the parkin mouse model could be a useful 
tool for further investigations of hippocampal functioning 
(Hanson et al. 2010; Rial et al. 2014).
The DJ-1 knockout mice are more sensitive to toxins 
and oxidative stress, but they do not display major neuronal 
abnormalities. Furthermore, the loss of DJ-1 function in 
mice can lead to motor deficits as well as to alterations in 
nigrostriatal dopaminergic function (Chen et al. 2005).
Behavioral tests to assess neurological status and the 
response to pharmacological treatments have been devel-
oped for these models. The activity test in the open field 
and the rotarod test for coordination are the most commonly 
used to assess motor function, although they lack the sen-
sitivity to detect subtle alterations in the nigrostriatal dopa-
mine system (Fleming et al. 2013). Other common tests are 
the sucrose preference, the tail-suspension and the forced 
swimming tests, which allow detection of signs of depres-
sion, and the elevated plus maze and marble burying tests, 
which highlight signs of anxiety (Bonito-Oliva et al. 2014; 
Gorton et al. 2010). A battery of tests more sensitive to dif-
ferent aspects of sensory and motor function and to subtle 
changes in basal ganglia function are the challenging beam 
traversal, which evaluates motor performance and coordina-
tion; the pole test, to assess basal ganglia-related movement 
disorders; the spontaneous activity in a cylinder; the inverted 
grid; the bin cotton use; the gait analysis; and the adhesive 
removal tests (Fleming et al. 2004, 2013).
Other behavioral assessments have been developed 
to evaluate the efficacy of therapies for non-motor symp-
toms. The identification of these non-motor symptoms is 
very important because some mouse models do not present 
motor deficits at all. As olfactory disturbances are the first 
non-motor symptoms observed in PD, behavioral testing, 
such as the buried pellet test, can be used to study this func-
tion and can facilitate early detection (Fleming et al. 2008). 
Both α-synuclein and MPTP mice took longer to find a bur-
ied pellet than their wild-type littermates (Fleming et al. 
2008; Baranyi et al. 2016). Sleep dysfunction is another 
important non-motor sign of PD in humans. During sleep, 
mice exhibit a distinctive posture and breathing pattern that 
allows the observer to determine the onset of the sleep. 
Thus, the time of latency before the mice begin this behav-
ior is easily recordable and comparable between strains (for 
review, see Taylor et al. 2010). Furthermore, some authors 
describe gastrointestinal dysfunctions similar to the ones 
reported in PD patients. Screening for such dysfunctions in 
mice can be performed using the solid gastric emptying test, 
which evaluates stomach motility, and the stool collection 
test, to examine colon motility (Taylor et al. 2009). Other 
non-motor signs are anxiety and depression, which could 
be evaluated using the elevated plus maze, open field test-
ing, and light–dark exploration, whereas cognitive deficits 
can be evaluated using the radial arm maze functions and 
the modified water maze (for review, see Taylor et al. 2010).
Parkin-deficient mice display normal performance on 
behavioral tests evaluating olfactory function, anxiety, 
depressive-like behavior tested with forced swimming and 
tail suspension, and motor function verified by the rotarod, 
grasping strength and pole tests. However, Parkin-deficient 
mice show poor performances in the open field habitua-
tion, object location and modified Y-maze tasks, suggest-
ing procedural and short-term spatial memory deficits (Rial 
et al. 2014). Hence, this model is useful for studying new 
therapeutic strategies to restore the learning, memory and 
synaptic plasticity impairments that are characteristic of PD 
(Rial et al. 2014).
The MPTP/p model shows impaired ambulatory behav-
ioral in the open field test and the pole test, due to an irre-
versible state of bradykinesia, and increased immobility 
in the bar test, compatible with catatonia (Rekha and Sel-
vakumar 2014). Furthermore, increased anxiety has been 
measured by the marble burying test in this model (Gorton 
et al. 2010). A partial bilateral lesion of the dorsal striatum 
with 6-OHDA results in a subtle impairment of gait dynam-
ics, accompanied by olfactory deficit and depression- and 
anxiety-like behavior. The mild motor impairment indicates 
that this model reproduces a relatively early stage of PD 
(Bonito-Oliva et al. 2014). Unlike the MPTP model, the 
6-OHDA mice do not display any reduction in horizontal 
motor activity and show normal stride length and frequency. 
Nonetheless, bilateral injection of 6-OHDA into the stria-
tum increases the immobility time in the forced swimming 
and tail suspension tests (Bonito-Oliva et al. 2014). In this 
model, subtle impairments of gait dynamics and reduced 
olfactory discrimination, reminiscent of early stage PD, 
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are accompanied by depressive and anxiety-like behaviors 
(Bonito-Oliva et al. 2014). However, the unilateral injection 
of 6-OHDA into the medial forebrain bundle results in total 
denervation of the dopaminergic nigrostriatal pathway. This 
partial lesion model is assessed by a battery of tests that are 
specific for this model, i.e., the cylinder, stepping, corridor 
and rotation tests (Boix et al. 2015).
The α-synuclein models display progressive sensorimotor 
anomalies, altered response to dopaminergic drugs, altera-
tions in striatal dopamine receptor function, and olfactory 
deficits (Fleming et al. 2004). The Thy1-aSYN mice made 
significantly more errors per step than their wild-type coun-
terparts in the beam traversal task, and they also showed a 
significant deficit on the pole test (Fernagut et al. 2007).
The PQ-intoxicated mice displays signs of increased hip-
pocampal oxidative stress and impaired memory function in 
the MWM, as well as reduced exploration of a novel open 
field arena, with females apparently less susceptible than 
male mice (Litteljohn et al. 2011).
Evidence of vascular changes in PD
In humans, both BBB and vascular damage have been 
reported in PD. Studies with PET have shown decreased 
regional CBF and oxygen utilization (Sarkar et al. 2014). 
Examinations with SPECT displayed a reduction of regional 
CBF in the temporal and parietal cortices in PD patients 
with or without dementia, as well as cortical blood flow 
alterations in PD patients with dementia (Sarkar et al. 2014; 
Varma et al. 1997). Immunohistochemical studies on micro-
vasculature changes in MPTP mice showed reductions in 
length and number, sclerosis and ischemia. Moreover, vessel 
density was also dramatically reduced in the striatum and 
SN (Fig. 4) (Sarkar et al. 2014).
There is growing interest in the evaluation of VEGF in 
neurodegenerative disorders, and generally in neuroprotec-
tion (Storkebaum et al. 2004). The intrastriatal implantation 
of encapsulated VEGF-secreting cells has been reported to 
exert beneficial effects in a PD model, effects that persisted 
for at least 8 weeks (Yasuhara et al. 2004). VEGF itself may 
have a direct neuroprotective effect on dopaminergic neu-
rons. The rescue of dopaminergic neurons from 6-OHDA 
lesions in the striatum and in the SN of VEGF-treated 
animals has been demonstrated by immunohistochemistry 
(Yasuhara et al. 2004). However, once the dose of VEGF 
exceeds the limit, its adverse effects might exceed the neu-
roprotective effects, causing deterioration in dopaminergic 
neuronal survival and function (Yasuhara et al. 2004).
The inflammatory process involved in microglia trigger-
ing is one of the key processes in PD. The peptide angio-
tensin II, via type 1 receptors, is among the most important 
inflammation and oxidative stress inducers and produces 
reactive oxygen species. The brain possesses a local angio-
tensin system that modulates striatal dopamine release. 
Angiotensin II may normally be involved in the modula-
tion of dopaminergic neurotransmission and may enhance 
the microglial/inflammatory response after an initial lesion 
induced by neurotoxins such as MPTP. This response is 
amplified by angiotensin II and inhibited by angiotensin 
type 1 receptor antagonists, both in vivo and in vitro (Joglar 
et al. 2009).
Preclinical imaging in PD
In vivo imaging, especially MRI and nuclear imaging tech-
niques, are a useful tool to evaluate PD progression and 
response to therapy. MPTP administration is not only known 
to cause disturbances in neural cell proliferation and dif-
ferentiation, due to dopamine depletion but also to evoke an 
inflammatory reaction, such as the accumulation of micro-
glia, lymphocytic infiltration and an increase in cytokine 
production, in the affected brain areas (Klein et al. 2014). 
These inflammatory responses might also be correlated to 
the transient increase in brain elasticity (Klein et al. 2014). 
In fact, a correlation between the steep transient rise in 
elasticity within the hippocampal region of up to over 50%, 
6 days after MPTP treatment, and an increased neuronal 
density in the dentate gyrus, which could not be detected in 
healthy controls, was demonstrated by magnetic resonance 
elastography (MRE) (Klein et al. 2014). This technique has 
proven to be useful in analyzing the correlation between 
morphological brain changes and dopamine depletion (Klein 
et al. 2014).
While BOLD fMRI is used to map the neurological sub-
strate of motor and cognitive symptoms in PD, activation-
induced, manganese-enhanced MRI can also be used for the 
non-invasive investigation of whole brain activity, indepen-
dently from blood hemodynamics and direct study of the 
neuronal activity. It can be used to diagnose PD but poten-
tially also for the study and diagnosis of various other neu-
rological disorders (Kikuta et al. 2015). With this method, 
it was possible to identify elevated striatal activity in MPTP 
mice (Kikuta et al. 2015).
To obtain a biomarker of brain function in PD, MRI 
spectroscopy is the method of choice to evaluate brain 
metabolism with quantitative measurements. Spectros-
copy revealed a decreased N-acetyl-aspartate to creatine 
ratio in the striatum of PD patients (Bagga et al. 2013). 
A novel spectroscopic approach, with the infusion of 
[1,6-13C2]-glucose or [2-13C]-acetate, was used to assess 
the glutamatergic, gamma-aminobutyric-acid-(GABA)-
ergic and astroglial function in different brain regions of 
mice exposed to MPTP (Bagga et al. 2013). This tech-
nique allowed the identification of dysfunction in the 
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Fig. 4  Series of coronal sec-
tions at the level of CPu puta-
men and SNc from control and 
MPTP treated mice brain. Mor-
phologically, FT-gel labeling in 
the saline treated animals was 
uniformly distributed within 
the capillaries in CPu (a) SNc 
(b). In acutely treated animals, 
both in CPu (c) and SNc (d) 
blood vessels were shorter, 
regressed, fainter in appear-
ance and ischemic (arrows). In 
the sub-acute treated animals, 
both in CPu (e) and SNc (f), the 
capillaries was dense in some 
parts forming the ‘clusters’ of 
various shapes and sizes with 
little or no staining between 
the ‘clusters’ (arrows). In the 
CPu (g) and SNc (h) of chronic 
treated mice, blood vessels 
were more regressed, more 
pronounced endothelial cell 
clusters (arrows) were apparent 
as compared to their saline 
treated counterparts (a and b). 
Scale bar: 100 µm. Structural 
abbreviations: CPu: striatum. 
(Sarkar et al. 2014)
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glutamatergic and GABAergic neuronal activities in the 
olfactory bulb in MPTP mice, as well as impairment of the 
excitatory and inhibitory pathways in brain regions that are 
involved in regulating movement and in the olfactory bulb 
and cerebellum (Bagga et al. 2013).
The PET- and SPECT-based methods of imaging DAT-
binding radiotracers are widely used to assess the integrity of 
the nigrostriatal projection in vivo (Fig. 5) (Alvarez-Fischer 
et al. 2007). The DAT SPECT tracers are used frequently 
in routine clinical studies to confirm or exclude the loss of 
nigrostriatal dopaminergic neurons in patients suspected to 
suffer from PD (Ziebell et al. 2012) This technique repre-
sents the main tool to determine DAT density in rodents, to 
test the effects of potential neuroprotective drugs (for review, 
see Suwijn et al. 2014).
The striatal  [123I]-FP-CIT SPECT signal in vivo corre-
lates with the DAT level, in both MPTP and 6-OHDA mice, 
but the main limitation of this method is that the number 
of nigral dopaminergic cells cannot be evaluated. However, 
 [123I]-FP-CIT pinhole SPECT allows more accurate detec-
tion of relatively large striatal DAT deficits in mice, i.e., 
losses of approximately 60–80% (Andringa et al. 2005). This 
approach may be useful for analyzing neuroprotective treat-
ments (Andringa et al. 2005).
Although 6-18fluoro-L-3,4-dihydroxyphenylalanine 
 ([18F]-DOPA) PET is considered the gold standard for the 
assessment of presynaptic dopaminergic integrity in vivo 
and is widely used in both patients and animal models, it is 
rapidly metabolized (Waerzeggers et al. 2010). To overcome 
this issue, 18F-dihydrotetrabenazine, a VMAT2 ligand with 
a prolonged half-life, has been used to examine changes in 
the dopaminergic system in MPTP mice. This tracer cor-
relates positively with the loss of dopaminergic neurons 
(Toomey et al. 2012). In addition, 2β-carbomethoxy-3β-
(4-chlorophenyl)-8-(2-[18F]-fluoroethyl)-nortropane is an 
established PET tracer for the DAT that has been success-
fully used in humans and monkeys. This tracer has clearly 
superior imaging characteristics compared with previously 
published ligands for the DAT (Honer et al. 2006). It dis-
plays very high accumulation in the right and left striatum, 
yielding PET images of high target-to-background ratios. 
Furthermore, its uptake in the striatum of MPTP mice was 
significantly reduced by 60% (Honer et al. 2006).
Neuroinflammation is another process involved in PD. 
Microglia activation, in response to pathological stimuli such 
as MPP+, 6-OHDA, or rotenone, has been studied in animal 
models of PD (Zhou et al. 2005). Imaging with appropriate 
radiotracers, e.g., radiolabeled isoquinolone PK11195, can 
track the in vivo distribution of activated microglia (Venneti 
et al. 2009). In MPTP and 6-OHDA models studied with PET, 
an immediate inflammatory reaction to the toxic insult and a 
later stage reaction consistent with the ongoing neurodegen-
erative process were shown. Thus, this PET technique offers 
a tool for the location and characterization of disease activity.
Fig. 5  High resolution in vivo 
imaging of striatal DAT (left) 
compared with DAT autoradi-
ography (right). a Horizontal 
SPECT slice of the striatum, 
showing the possibility to dis-
tinguish sub-striatial structures 
through DAT binding of  [123I]
FP-CIT. b Autoradiogram at the 
level of the striatum and olfac-
tory tubercle of a mouse brain 
post mortem. Please note, that 
the autoradiography and SPECT 
images look similar, suggesting 
that pinhole SPECT is able to 
delineate DAT binding within a 
sub-millimeter range c SPECT 
slice overlaid on an anatomic 
brain atlas of the mouse. d 
Autoradiogram overlaid on 
anatomic brain atlas. DAT, 
dopamine transporter;  [123I]
FP-CIT,  [123I]N-o-fluoropropyl-
2b-carbomethoxy-3b-(4-iodo-
phenyl)- nortropane; SPECT, 
single photon emission com-
puted tomography. (Vastenhouw 
et al. 2007)
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Moreover, in MPTP mice, a specific apoptosis-target-
ing peptide, linked to fluorescent dye, was used to study 
in vivo dopaminergic neurons death. It was demonstrated 
the feasibility of these approach, evaluated by a fluorescence 
molecular imaging system, even in the assessment of drugs 
efiiciency (Lee et al. 2012).
Mouse models of Huntington’s disease
Huntington’s Disease (HD) is a neurodegenerative disorder 
characterized mainly by the loss of medium spiny neurons 
(MSNs) in the striatum, caudate nucleus and putamen of 
the basal ganglia and by the degeneration of the cortex and 
hippocampus, resulting in chorea, dystonia, psychiatric and 
cognitive abnormalities (Glorioso et al. 2015). As observed 
in other neurodegenerative diseases, there is no single mouse 
model that summarizes all the characteristics of HD. In par-
ticular, chorea is a symptom restricted to primates (for review, 
see Heng et al. 2008). Mouse models are classified into two 
categories: toxin-induced and genetic models; the latter cat-
egory is further divided into transgenic and knock-in models.
The two most common toxin-induced models are produced 
by the administration of quinolinic acid (QA) and 3-nitropro-
pionic acid (3-NP). The QA administration mimics the early 
stage of HD, reproducing hyperactivity. The cognitive deficits 
are detectable by the MWM, the radial arm water maze, and 
the T-maze (Furtado and Mazurek 1996; Shear et al. 1998).
The 3-NP model is a mitochondrial dysfunction model 
and resembles the later stage of HD, characterized by motor 
disorders and related striatal damage, which are tested using 
the pole, the rotarod, the stride length, and the open-field 
spontaneous activity tests (Fernagut et al. 2002).
Among the transgenic models, R6/2 is the most used. 
As the onset of symptoms is at 5 to 6 weeks of age, R6/2 
is considered a model of juvenile disease (Parievsky et al. 
2012; Chang et al. 2015). In contrast to human HD, the R6/2 
brains do not show a massive neuronal loss (for review, see 
Wang and Qin 2006). The mice display a severe phenotype 
with low weight, diabetes, clasping, tremor and convulsions 
(Wang et al. 2005). The main behavioral signs are motor 
deficits, occurring as early as 40 days of age, and hyperac-
tivity, verified using the open-field test for locomotion and 
exploratory behavior. Cognitive deficits appear before the 
motor symptoms and can be confirmed by the MWM and 
the T-maze tasks. Both tests require the subjects to replace a 
previously learned strategy using their intact fronto-striatal 
circuitry (for review, see Ramaswamy et al. 2007).
The R6/1 model is less common than the R6/2 model 
and shows a mild behavioral phenotype. Aberrant synaptic 
plasticity has been described in these mice (for review, see 
Cepeda et al. 2010). The behavioral tests used to evaluate 
R6/1 deficits include footprint analysis, which evaluates 
gait abnormalities, decreased anxiety, and hindlimb clasp-
ing behavior (Denny et al. 2010). Even though the R6/2 and 
R6/1 models are not the most genetically accurate, thus far, 
they represent the most feasible models for therapeutics 
research, as the outcomes are more prevalent and definable 
(for review, see Wang and Qin 2006).
Mouse models expressing yeast artificial chromosome 
(YAC) htt are more genetically accurate but have a more 
variable and subtle phenotype. They are characterized by 
atrophy and neuronal loss in the striatum (Berggren et al. 
2016).
The most used among YAC models is YAC128, which 
shows hyperkinetic abnormalities at 3 months of age and 
hypokinesia at 6 months of age in the open field and rotarod 
tests. Furthermore, examining YAC128 mice with the swim-
ming T-maze reveals difficulties in forming new strategies 
(Van Raamsdonk et al. 2005).
The N171-82Q mouse model expresses a human htt gene 
and represents a good model for adult HD. At the onset, 
the mice display resting tremor, hypokinesia, hindlimb and 
forelimb clasping, and abnormal gait. At 14 weeks of age, 
they show deficits of working and reference memory in the 
radial arm water maze test (for review, see Ramaswamy 
et al. 2007). At 4 to 6 weeks before death, they show tremor, 
hypokinesis, and clasping (Heng et al. 2008). The later onset 
of behavioral symptoms and the protracted time course make 
this model ideal for the study of presymptomatic therapies.
Knock-in mouse models are generated by replacing 
a portion of the murine htt gene with the human mutant 
copy, which contains an expansion of the CAG region. 
Such expansion is directly proportional to the precocity of 
symptoms onset, in both rodents and humans (Fernandes 
and Raymond 2009). The knock-in models are the most 
representative of genetic and protein alterations, although 
they are not appropriate for behavioral studies. For example, 
knock-in HdhQ111 mice do not show behavioral deficien-
cies compared to the controls when subjected to specific 
tasks (for review, see Ramaswamy et al. 2007). Nonetheless, 
they recapitulate an important pathological change observed 
in the HD human brain, i.e., the preferential accumulation 
of mutant htt in the striatal neurons (for review, see Chang 
et al. 2015). However, homozygous knock-in mice show very 
early behavioral anomalies, prior to any detectable neuro-
pathology. Behavioral abnormalities can be evaluated in 
the knock-in CAG140 and CAG150 models. The first was 
rotarod deficit at 9 months, the latter at 4 months (for review, 
see Ramaswamy et al. 2007).
Evidence of vascular changes in HD
Changes in the morphology of microglia, when activated by 
any brain insult, are accompanied by vascular changes due 
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to the persistent secretion of pro-inflammatory factors. This 
activation may be involved in the pathogenesis of HD, as 
confirmed by microglia activation in the R6/2 and YAC128 
models (Franciosi et al. 2012). The progression of HD may 
be studied by evaluating pro-inflammatory markers in the 
plasma in R6/2 mice, but most of the studies showed some 
limitations, such as small sample size and differences in 
baseline characteristics between the study groups, so the cor-
relation between disease progression and inflammation has 
not yet been confirmed (for review, see Chang et al. 2015).
Cerebral hyperperfusion has been reported in HD patients 
and mice and is observed as increased vessel density, CBV 
and/or CBF (Hua et al. 2014). Longitudinal studies using fMRI 
showed functional and morphological changes in the cerebral 
blood vessels and alteration in the BBB in R6/2 mice. In par-
ticular, a decrease in blood vessels size and atrophy of the 
putamen have been detected. Hence, the reduction in oxygen 
supply triggers a compensatory mechanism, which leads to the 
increase in vascularization and in arterial CBV, particularly in 
the grey matter of HD patients and R6/2 mice (Drouin-Ouellet 
et al. 2015). The evaluation of microvessels and BBB using 
μMRA and dynamic CE MRI showed significant increases in 
vessel density and CBV, but not in vessel size, in R6/2 mice 
as early as 7 weeks of age. These changes in vessel density 
in the cortex and striatum preceded any behavioral aberra-
tions and worsened with disease progression, with no apparent 
concomitant disruption of the BBB (Lin et al. 2013). These 
studies underline a correlation between vascular impairment 
and neurodegeneration. If these phenomena are confirmed in 
the early stages of the clinical HD, they can be considered as 
targets for future therapies (Waldvogel et al. 2015).
Vascular impairment has also been studied in the R6/1 
model by myography. The R6/1 model presented reduced con-
tractility in arteries from several different vascular beds, prob-
ably due to altered calcium fluctuations in the arterial smooth 
muscle cells (Rahman et al. 2013). This mouse model displayed 
alterations in peripheral arterial resistance form 12 weeks of 
age due to an impairment of nitric oxide (NO) -dependent 
mechanisms. Moreover these mice did not exhibit endothe-
lial relaxation between 12 and 16 weeks, and they showed 
significant enhancement of endothelial-dependent dilation 
and impaired vasoconstrictor responses (Kane et al. 2016). 
It should be remembered the importance of the equilibrium 
between superoxide  (O2−) and NO in maintaining the physi-
ologic vascular tone: a NO increase would lead to vasodilation; 
on the other hand, the  O2− increase is linked to vasoconstriction 
and increased peripheral vascular resistance (Kane et al. 2016) 
The production of  O2− may be due to several factors, including 
huntingtin effects and mitochondrial damage (Rahman et al. 
2013; Kane et al. 2016). Finally, the impaired vascular reactiv-
ity, i.e. the ability of the blood vessel to control the CBV in 
response to hemodynamic changes detected in R6/2 mice with 
MRI, seems to be induced by aberrant HD astrocytes via an 
increased VEGF-A production (Hsiao et al. 2015).
Preclinical imaging in HD
The technique most commonly used for the study of HD 
mouse models is MRI. MRI allows the characterization of 
several neuroanatomical features in the brains of YAC128 
mice, including the striatal volume decrease as of 8 months 
of life and an asymmetric atrophy, similar to observations 
in HD patients (Lerch et al. 2008). To the best of our knowl-
edge, R6/2 mice are the most commonly used to character-
ize MRI in HD. The ex vivo MRI analysis of R6/2 brains 
showed morphological changes, such as reduced striatal and 
increased ventricular volumes, and demonstrated a good cor-
relation between the MRI results and traditional histology 
(Sawiak et al. 2009).
In vivo MRI studies have been demonstrated to be more 
accurate than ex vivo, although the scanning time, con-
trasts and image resolution are the main limitations of the 
technique (Zhang et al. 2010). The first results of in vivo 
MRI in HD models revealed the opportunity to detect 
atrophy before the onset of motor symptoms (Zhang et al. 
2010). In vivo MRI performed in HdhQ150 showed global 
brain atrophy before the onset of motor signs, although, 
unlike HD patients, alteration in white matter region have 
not been showed in corpus callosum (Steventon et  al. 
2016). The R6/2 mouse models showed atrophy of the cor-
tex and the striatum. Such lesions can be visualized from 
the third week of age, and significant progressive atrophy 
in the R6/2 cortex was observed mainly in the early post-
natal phase, becoming less evident in later stages, up to 
5 weeks of age (Fig. 6) (Aggarwal et al. 2012). Measuring 
the brain volume by T2 MRI, it is possible to evaluate the 
effect of therapy. The R6/2 model is not adequate for this 
purpose, since brain atrophy is evident from 3 to 5 weeks 
of age, and hence the time is too short to assess the ther-
apy effectiveness (Aggarwal et al. 2012). The N171-82Q 
model represents a less severe phenotype compared to 
R6/2. This model allows evaluating brain atrophy using 
MRI in response to Sertraline, a neuroprotective agent, 
from 6 weeks of age. These results confirm that MRI is 
useful not only to test the effectiveness of therapy, but also 
in the selection of the murine model, which possesses the 
most adequate characteristics, e.g. time of onset, to study 
drug efficiency or specific pathological processes (Cheng 
et al. 2011).
The detection of cerebral functional alterations using 
MRI proved to be useful in studying HD progression, as 
these alterations are detectable before structural changes 
become apparent. Relative CBV alterations in the striatum, 
temporal cortex, primary motor cortex, and prefrontal motor 
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cortex can all be detected in early symptomatic R6/2 mice. 
Therefore, relative CBV measurements may serve as a bio-
marker of HD and can be used to evaluate the effects of 
therapies (Parievsky et al. 2012). The CBV alteration has 
been found also in YAC 128 mouse, in the dorsal striatum 
and in a region homologous to the posterior caudate in 
humans, confirming human data (Lewandowski et al. 2013). 
The “energy deficit,” a decrease in metabolism displayed 
by HD patients, has been confirmed in HD models by a 
reduction of the signal from brown adipose tissue in MRI 
Fig. 6  Spatiotemporally-varying rate of atrophy in the R6/2 mouse 
model of HD. a Color-coded maps showing the average rate of atro-
phy in the week 3 to 5 and week 5 to 12 age spans are overlaid on 
orthogonal sections from the reference atlas. The color bar represents 
the difference in fitted slopes of log-Jacobian between the R6/2 and 
wild-type control cohorts, with negative values indicating progressive 
atrophy in the R6/2 brain compared to controls. b Statistical maps 
(false discovery rate = 0.05) showing regions with significant differ-
ences in the fitted slopes of log-Jacobian between the R6/2 and con-
trol brains overlaid on the reference atlas. The log-Jacobian profiles at 
selected voxel locations are plotted in (c), showing the individual tra-
jectories (open circles) and the overall LME model fit (bold lines) for 
the wild-type (WT) and R6/2 cohorts. Structural abbreviations are: 
Cx: cerebral cortex, Cb: cerebellum, CPu: striatum, Hi: hippocampus, 
LV: lateral ventricle, Th: thalamus. (Aggarwal et al. 2012)
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(Lindenberg et al. 2014). Moreover, the glutamate plays an 
essential role in synaptic transmission and neuronal excit-
ability, through the interaction with metabotropic receptors 
as metabotropic glutamate receptor (mGluR) 1 and mGluR5. 
In fact, the HD resulted to be characterized by a decrease 
of mGluR1 (Yamasaki et al. 2014). To better understand 
the role of glutamate in HD, Chemical Exchange Saturation 
Transfer imaging of glutamate (gluCEST) was developed to 
map glutamate distribution in the brain of a knock-in mouse 
model of HD. The T2 weghited MRI with gluCEST contrast 
have showed altered metabolic profile in striatum and corpus 
callosum in knock-in CAG140 model (Pépin et al. 2016).
In vivo PET/CT has been used with  [11C]-methylbenzamide 
to quantify the mGluR 1 decline in HD models, leading to 
a better understanding of its action in the pathophysiology 
of neuorodegenerative disorders (Yamasaki et  al. 2014). 
The PET/CT technique also allowed the specific evaluation 
of the striatal MSNs’ expression of phosphodiesterase 10A 
(PDE10A), a regulator of striatum signaling, using a novel 
 [11C]-radioligand (Tóth et al. 2015). The radioligand  [11C]
T-773, has showed high affinity for PDE10A, with higher 
uptake in the striatum of PDE10A knock-out mice compared 
to control mice. Further studies will allow identifying other 
targets of PDE10A, reducing the activity of medium spiny 
neurons (Tóth et al. 2015).
Mouse models of multiple sclerosis
Multiple Sclerosis (MS) is a chronic inflammatory disease 
characterized by demyelination and axonal damage, leading 
to motor and cognitive dysfunction (Peruga et al. 2011). The 
MS is a complex disease that can manifests different symp-
toms and clinical signs. However, it is categorized into three 
classes based on the clinical course: the relapsing-remitting 
(RR), the Secondary Progressive, and the Primary progres-
sive forms (for review, see Procaccini et al. 2015). To date, 
effective treatments for MS are unavailable, and for this rea-
son different mouse models have been developed to study 
the different aspects of this complex pathology, such as 
immunological aspects and motor symptoms, as well as the 
de-re-myelination processes. The three mouse models of MS 
are: the experimental autoimmune/allergic encephalomyeli-
tis (EAE); the virally induced chronic demyelinating dis-
ease, induced by Theiler’s murine encephalomyelitis virus 
(TMEV) infection, and the toxin-induced demyelination.
The EAE mouse model is the most commonly used to 
study MS, as it enclose all the pathological features of MS, 
i.e. inflammation, demyelination, axonal loss and gliosis. 
This model is induced by the administration of antigens like 
the myelin basic protein (MBP) or the proteolipid protein 
(PLP), emulsified with complete Freund’s adjuvant (CFA) 
or incomplete Freund’s adjuvant (ICF), and followed by 
pertussis toxin administration, which allows efficient induc-
tion of active disease (Miller et al. 2007). The EAE model 
can reproduce both the RR than the primary progressive 
forms of MS depending on the mice genetic background, 
the antigen used for immunization and the immunization 
protocol itself (Berard et al. 2010; Dehghan et al. 2016). 
The RR form is reproduced with the subcutaneous injection 
of the immunodominant epitope of the PLP  (PLP139 − 151) in 
SJL/J mice; this model is used to study the pathogenesis and 
immune-regulation of T cell–mediated demyelination. On 
the other hand, the disease induced by the immunodominant 
 MOG35 − 55 peptide in C57BL6/J mice is of chronic nature, 
and it represents a good approximation of the primary pro-
gressive human disease. The latter model is used to clarify 
the role of the immune system in the pathogenesis of MS, 
and the specific contribution of B cells, monocytes,  CD8+ 
and  CD4+ T cells (Berard et al. 2010).
Following the EAE immunization, mice develop an 
ascending flaccid paralysis, which is classified by a clinical 
score (Miller et al. 2007).
Among motor test, Rotarod test and Foot print analysis 
are the most useful in EAE, since they allow detecting dis-
abilities earlier compared to the clinical score. Indeed, the 
EAE mice showed motor skills impairment in rotaroad test 
and footprint analysis, when the clinical score was still “nor-
mal” (Takemiya and Takeuchi 2013; Van den Berg et al. 
2016). Behavioral investigation about anxiety and depression 
in EAE showed some conflicting results. Rodrigues and coll. 
analyzed memory and anxiety in animals using the elevated 
plus maze, the step inhibitory avoidance task and the object 
recognition test, and no differences were detectable between 
controls and EAE mice in any of the tests. In contrast, some 
studies showed deficit in memory using the MWM, as well 
as increased anxiety, measured by the elevated plus maze 
and the light/dark box, and depression-like behavior when 
performing forced swim and tail suspension tests (Acharjee 
et al. 2013). These cognitive alterations are associated to 
the neuroinflammatory process, which induces an increased 
level of IL-1b and TNF-a in the hypothalamus accompa-
nied by increased corticosterone levels and hence changes 
in emotional and cognitive behavior (Acharjee et al. 2013).
The TMEV is a pathogen that infects only mice and 
induces chronic progressive inflammatory demyelinating 
disease. Different TMEV types are used: the GDVII type 
is highly virulent and it induces death within 1 to 2 weeks, 
whereas the TO type, which include the Daniels (DA) 
and the BeAn8386 (BeAn) strains, induces an acute poly-
encephalomyelitis (for review, see Procaccini et al. 2015). 
Two to 3 weeks post infection with the DA strain, mice 
develop a spastic paresis of the hind limbs, progressing in a 
severe spastic paralysis. In contrast, infection of SJL/J mice 
with the culture-adapted BeAn 8386 strain does not pro-
duce clinical evidence of a first-phase disease. Infected mice 
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begin to show clinical signs between 30 and 40 days post 
infection and they develop a chronic, progressive paralysis 
with no recovery or remitting episodes, similar to the pri-
mary progressive MS (McCarthy et al. 2012). The rotarod 
revealed to be effective in the evaluation of motor disabilities 
also in this model, beginning from the third month post-
infection (Gilli et al. 2016). Furthermore, TMEV models 
suffer of thermal hyperalgesia and mechanical allodynia 
similarly to MS patients, evaluated by von Frey filament 
(Lynch et al. 2008).
The toxin-induced mouse model of demyelination is 
reproduce with the administration of toxic substances that 
cause demyelination, which can be reversed when the toxic 
substance is removed, allowing re-myelination (Abakumova 
et al. 2015). The most common agents used are cuprizone 
and lysolecithin. Cuprizone induces widespread demyelina-
tion in white and gray matter, affecting in particular oligo-
dendrocytes, which die by apoptosis due to metabolic failure 
triggered by the chelating properties of cuprizone itself.
Behavioral tests for toxin model must be enough sensi-
tive to reveal the de- and re-myelination effect. The modi-
fied wheel running test has been performed to reveals latent 
motor deficit in the cuprizone model, both during demyeli-
nation than remyelination. In this test, mice are first trained 
to run on a wheels composed of regularly spaced cross-
bars till maximal wheel-running performance is achieved. 
Subsequently, mice are exposed to wheels with irregularly 
spaced crossbars (complex wheel) demanding high-level 
motor coordination. Interestingly, mice fed with cuprizone 
diet showed motor impairment as compared to control mice 
both in simple than complex wheel. In contrast the remyeli-
nated mice showed normal performance in simple wheel, but 
motor impairment in the complex wheel, indicating a latent 
motor skill deficit (Liebetanz and Merkler 2006). Elevated 
plus maze, as well as rotarod, did not show any symptoms 
recovery after 2 weeks of cuprizone deprivation, probably 
due a delayed remyelination after chronic demyelination 
(Abakumova et al. 2015).
Evidence of vascular changes in MS
The demyelinating lesions both in MS and in EAE are asso-
ciated with an increased VEGF expression (Roscoe et al. 
2009). In the EAE, the VEGF is expressed by astrocytes, 
monocytes and activated Th1 lymphocytes, all contributing 
to BBB breakdown. The inflammatory cells infiltrating the 
CNS trigger the pathophysiological processes behind MS, 
and promote and stimulate the angiogenesis. Some studies 
reported that angiogenesis in EAE is detectable in gray mat-
ter and the leptomeninges (Macmillan et al. 2011); more 
recently, an increase in vessels number and size has been 
showed in the area surrounding the demyelinating plaques 
(for review, see Lengfeld et al. 2014). Several factors con-
tribute to the angiogenetic process, e.g. ipoxia, which induce 
releasing of VEGF, and macrophages of M2 phenotype, 
which are expressed in EAE mice during acute phase and 
remission. The M2 macrophages promote angiogenesis by 
producing Fibroblast growth factor (FGF), VEGF, platelet-
derived growth factor (PDGF) and metalloproteinase, which 
are able to digest components of the extracellular matrix, 
facilitating immune cell infiltration into the CNS in the con-
text of both MS and EAE (for review, see Lengfeld et al. 
2014).
During EAE progression, an increased neuronal VEGF 
expression has been described in the early phase, correlated 
to the clinical score, while there are reductions in angiopoie-
tin-1 and angiopoietin receptor Tie-2. By day 21 post induc-
tion, VEGF was markedly reduced, levels of angiopoietin-1 
and angiopoietin-2 were augmented, this event corresponds 
with angiogenesis peak in gray matter and adjacent to the 
leptomeninges. These vascular changes suggest the angio-
genesis implication in MS and EAE (Macmillan et al. 2011).
Recently, cerebrovascular remodeling has been demon-
strated during the pre-symptomatic phase of EAE in regions 
not yet demyelinated, while increased blood vessels density 
has been assessed at later stages. Although angiogenesis pre-
cedes the demyelination, and hence the clinical symptoms 
of EAE, it has not yet determined if it has an advantageous 
or a detrimental effect (Boroujerdi et al. 2013).
Some studies showed that the administration of anti-angi-
ogenic therapies during the acute phase of EAE produced 
a significant reduction of the process of demyelination and 
improved the clinical score (Roscoe et al. 2009). On the 
other hand, the increase in vessel number and size during 
EAE supports the release of trophic factor that enhances 
axonal remodeling and functional recovery (Muramatsu 
et al. 2012). Further studies are needed to evaluate the role 
played by angiogenesis in the progression of the disease. The 
inflammatory process affects cerebral and spinal cord gray 
matter in the early acute phase of TMEV models, while in 
the chronic phase the inflammatory infiltration is widespread 
to the spinal leptomeninges (for review, see Oleszak et al. 
2004).
Preclinical imaging in MS
The MRI is considered the gold standard for the diagno-
sis of MS. On the other hand, lesions revealed by MRI do 
not always correlate with the level of patients’ disability, 
thus the need for preclinical imaging studies (for review, 
see Nathoo et al. 2014). Thanks to MRI studies on EAE 
mice, it might be possible to find out if a correlation exists 
between imaging and cerebral lesions, i.e. demyelination, 
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BBB breakdown, level of inflammation and vascular defects 
(Fig. 7).
In the acute phase, two types of lesion are identified by 
2.35 T: strongly hypointense lesions on T1- and T2-weighted 
images, and isointense or slightly hypointense lesions on 
T1-weighted images, which result hyperintense on the cor-
responding T2-weighted images. Histopatological results 
confirmed that hypointense lesions on T1- and T2-weighted 
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correspond to axonal and myelin loss (Nessler et al. 2007). 
Axonal loss, characterized by hypointense areas, is observed 
in TMEV with T1 sequence. Brain atrophy has been dem-
onstrated in TMEV mouse by ventricular enlargement, 
assessed with T2- weighted imaging, which correlates with 
progression of disease and motor impairment (Paz Soldán 
et al. 2015). The MRI revealed the reduction of the corpus 
callosum volume and the presence of hyperintense foci in 
the cuprizone model (Abakumova et al. 2015). The remy-
elination process in the pathological foci, studied with 
T2-weighted MRI, was detectable 2 weeks after cuprizone 
withdrawal (Abakumova et al. 2015). Magnetization transfer 
ratio (MTR) has been used to evaluate myelin loss in MS 
lesion in the cuprizone model, whereas in the EAE model 
it does not correlate with demyelination (Fjær et al. 2015).
In order to study BBB breakdown, the administration of 
Gd-DTPA, is useful to reveals areas of cerebral enhance-
ment, which reflect the BBB disruption and thus early 
inflammation (Nessler et al. 2007). The Gd-based contrast 
agent, gadofluorine M (Gf) is more sensitive than other 
Gd chelates in detecting cerebral and spinal cord lesions 
BBB lesions, not seen with other contrast agents or in 
T2-weighted sequences (for review, see Nathoo et al. 2014).
The conjugate-nanoparticles for MRI is a useful tool 
for inflammatory lesions study. The vascular cell adhesion 
molecule (VCAM) is upregulated in MS and EAE, so that 
VCAM-Micrometer-sized iron oxide particles (MPIO) bind-
ing, is a good tool to study inflammation, as it is observed in 
the hindbrain and in the caudal part of the forebrain before 
both clinical signs and BBB breakdown appear (Serres et al. 
2011). Recently, the efficacy of myeloperoxidase (MPO)-Gd 
contrast agent has been assessed to evaluate anti-inflamma-
tory effect of the recombinant human form of gelsolin (rhp-
GSN) in the EAE brain. The group of mice treated with 
rhp-GSN showed decreasing both in MPO activity and in 
neuroinflammation. The MPO-Gd MRI performed during 
peak acute inflammation demonstrated larger lesions and 
stronger signal enhancement in the control group compared 
to the rhp-GSN treatment group (Li-Chun et  al. 2015). 
Imaging inflammation in TMEV has been carried out using 
T2 weighted imaging and USPIO, tracking inflammation 
and migration of specific cell types, including CD8 + and 
CD4 + T-cells.
Vascular alterations in EAE have been observed with T2* 
MRI as large hypointense vessels. Susceptibility-weighted 
imaging (SWI) is an MRI method that is very sensitive in 
analyzing venous vasculature, and in EAE mice it has been 
used to identify hypointensities due to intravascular deoxy-
hemoglobin (Nathoo et al. 2015).
Although MRI is the technique of choice to study MS and 
EAE, the PET imaging provides useful biological informa-
tion at the molecular level, before anatomical changes occur 
(Mattner et al. 2013). The PET allows the quantification of 
cerebral myelin taking advantage of the binding capacity 
with the beta-sheet structure of MBP of tracers, such as 
the Thioflavine-T derivative 2-(40-methylaminophenyl)-
6-hydroxybenzothiazole (PIB). This tracer has been already 
used to detect the plaques in AD, and it was able to detect 
demyelinated lesions in MS patients (Stankoff et al. 2011). 
The  [11C]-CIC and  [11C]-MeDAS, containing stilbene moi-
ety which bind beta-sheet structure as well, and are promis-
ing tracer for monitoring demyelination and remyelination 
processes. During the demyelination process, the beta sheet 
structure is lost, and consequently the link with the contrast 
decreases, resulting in reduced uptake. Interestingly, only 
the  [11C]-MeDAS was able to detect remyelination in the 
cuprizone mouse model (De Paula Faria et al. 2014).
The PET/CT has proved useful also for the detection of 
inflammation in EAE models, thanks to the use of  [18F]-FDG 
tracer. It allows the quantification of glycolysis in the spinal 
cord, which correlates with the onset of EAE neurological 
symptoms and with the presence of inflammatory infiltrates 
detected by histological analysis (Radu et al. 2007). The 
neuroinflammatory processes have been studied with sev-
eral tracers binding TSPO. Recently, The imidazopyridine 
 [18F]-PBR111 has been developed a sensitive radioligand of 
TSPO able to quantify the TSPO in the different RR phases 
of EAE, showing an increasing TSPO level in the first phase 
of disease correlated to mild to moderate clinical scores 
(Mattner et al. 2013).
Two-photon microscopy of EAE mice allowed observ-
ing axonal transport abnormalities evolution (for review, 
see Rougon et  al. 2016). The NIRF vascular imaging 
agent AngioSense demonstrated vascular leaks in the 
BBB in EAE mice by elevated cerebral f luorescence 
even in pre-symptomatic mice, as well as an elevated spi-
nal signal. Similarly, an increased protease activity was 
detected both in the brain and in the spinal chord of EAE 
mice (Eaton et al. 2013).
Fig. 7  Serial MRI of two distinct EAE lesions in one animal at days 
3, 9, 11 and 21 after disease onset. A typical evolution of a type A 
brainstem lesion with a persistent hypointense centre on both T1- and 
T2-weighted MRI and a fading hyperintense rim on T2-weighted 
MRI is depicted in A^H (left columns). Final histological examina-
tion demonstrates infiltration by foamy macrophages/microglia (I; 
Mac-3), myelin loss (J; MBP), marked reduction in axonal density 
(K; Bielschowsky) and perivascularly accentuated gliosis in the area 
of most prominent tissue damage (L; GFAP). The atypical lesion 
adjacent to the lateral ventricle (right columns, M ^T) is first seen at 
day 9 (O, P). Part of the signal intensity changes may be related to 
CSF leakage (O ^R). Histopathology reveals infiltration with mac-
rophages/microglia at day 21. Perivascular lymphocytic infiltrates are 
visible at the right lower image border (U; Mac-3). A circumscribed 
area of myelin loss is apparent (V; MBP). Axon density is reduced 
(W; Bielschowsky), and astrocytic gliosis is prominent around the 
lesion (X; GFAP). Rectangles in G, H, S and T indicate the respective 
areas depicted in histology (I^L and U^X). Original magnifications: 
I^L, U^X: 100; scale bar: X: 200 mm
◂
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Open questions in neurodegeneration
The cerebral parenchyma is completely separated from cir-
culating particles by the BBB, which prevents the leakage 
of molecules as well as of blood cells in the CNS. Hence, 
the CNS has a separate immune system, and microglial 
cells represent the equivalent of macrophages (for review, 
see Rougon et al. 2016). Among the etiopathogenetical 
theories on neuroinflammation and neurodegeneration, 
the escape of fibrinogen or the presence of micro-hem-
orrhages, due to BBB disruption, are advocated to play 
a key role as the primum movens in neuroinflammation 
(for review, see Zamboni 2006, for review, see; Hare et al. 
2013; Onida and Davies 2014, for review, see; Rougon 
et al. 2016). Fibrinogen has been demonstrated to sustain 
CNS inflammation by recruiting myelin antigen-specific 
Th1 lymphocytes, which lead to secondary demyelination, 
in different reporter fluorescent mouse strains studied with 
two photon in vivo imaging (for review, see Ryu et al. 
2015, for review, see; Rougon et al. 2016).
On the other hand, disturbances of cerebral venous 
outflow seem to lead to hemosiderin and excessive iron 
deposition and consequently to neuroinflammation, in 
accordance to the pathogenetic model of chronic venous 
disease of lower extremities (for review, see Zamboni 
2006; for review, see; Hare et al. 2013; Onida and Davies 
2014). Excess iron deposition and inflammatory lesions in 
the brain has been found in Alzheimer’s and Parkinson’s 
disease and in multiple sclerosis, as well as in the ageing 
brain (Onida and Davies 2014). To test the latter hypoth-
esis, after the study of Atkinson and coll. who failed to 
demonstrate a correlation between cerebral venous out-
flow disruption and neuroinflammation/demyelination 
(Atkinson et al. 2012), our group recently set up a new 
and more aggressive surgical model of cerebral venous 
outflow occlusion (Auletta et al. 2017).
Iron oxide-labeled stem cells have been used in MS as well 
as ALS patients, but their tracking with MRI failed to allow a 
long term monitoring. In mouse models of ALS, an alterna-
tive tracking methods has been used, whit the aid of OI (bio-
luminescence) to non-invasively and longitudinally observe 
the fate of stem cells. In this case, stem cells were attacked 
by the host immune system, which is probably enhanced by 
the ALS hostile microenvironment (Srivastava et al. 2017).
In any case, efforts in developing new mouse models and 
new imaging technologies should continue to test etiopatho-
genetical theories as well as new therapies.
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